Document:

Master Development, Manufacturing & Supply Agreement

 Exhibit 10.8 
  
 Confidential treatment has been requested for portions of this exhibit. The copy filed herewith omits the information subject to the
confidentiality request. Omissions are designated as [*]. A complete version of this exhibit has been filed separately with the Securities and Exchange Commission pursuant to Rule 406 of the Securities Act of 1933, as amended. 
  
 MASTER DEVELOPMENT, 
 MANUFACTURING AND SUPPLY AGREEMENT 
  
 This Master Development, Manufacturing and Supply Agreement (this “Agreement”), Second Amended and Restated dated as of the 19th day of March,
2003, by and between ENABLE MEDICAL CORPORATION, a Delaware corporation with offices at 6345 Centre Park Drive, West Chester, Ohio 45069 (“Enable”), and ATRICURE, INC., a Delaware corporation with offices at 6033 Schumacher Park Drive,
West Chester. Ohio 45069 (“AtriCure”), AtriCure and Enable may be referred to collectively as the “Parties” or individually as a “Party.” 
  
 W I T N E S S E T H : 
  
 WHEREAS, AtriCure is in the business of developing and manufacturing certain RF atrial ablation generators (the “AtriCure Generators”) and
devices; and 
  
 WHEREAS, Enable is in the business of providing
development, engineering and manufacturing of certain medical devices and other applications; and 
  
 WHEREAS, AtriCure wished to engage Enable to (i) provide AtriCure with certain development services with respect to electrosurgical devices for use in
conjunction with the AtriCure Generators, and (ii) manufacture for AtriCure its requirements (requirements as outlined in Exhibit A of this agreement) with respect to three electrosurgical devices, and Enable wished to accept such engagement; and

  
 WHEREAS, in order to memorialize the foregoing engagement,
AtriCure and Enable entered into a Amended and Restated First Master Development, Manufacturing and Supply Agreement, dated as of October 2, 2002 (“Amended and Restated Agreement”); and 
  
 WHEREAS, AtriCure and Enable desire to replace the Amended and Restated
Agreement upon the terms and conditions hereinafter set forth. 
  
 NOW, THEREFORE, in consideration of the mutual covenants and agreements herein contained, the Parties hereby agree as follows: 
  
 Summary of Coverage of Agreement 
  
 This Agreement principally covers the following, as more fully set forth below and subject to the terms and conditions set forth below: 
  

	 	1.	Certain development services to be provided by Enable to AtriCure with respect to the electrosurgical devices as set forth in Exhibit A, hereto, (such electrosurgical devices being
sometimes hereinafter referred to, collectively, as the “Devices”). 

  

	 	2.	Certain manufacturing services to be provided by Enable to AtriCure with respect to the electrosurgical devices as set forth in Exhibit B hereto. 

  
  

					
	 EMC-ATR Agreement March 24, 2003-2
	  	1	  	 

	 	3.	The licensing of certain Enable Technology to AtriCure, of certain AtriCure Technology to Enable, and of certain jointly created technology between the Parties in the Field of Use,
which is the therapeutic ablation treatment for cardiac arrhythmia. 

  

	 	4.	The limited use of certain Enable facilities, software, and equipment as set forth below. 

  
 Definitions 
  

	1.	Field of Use – means the therapeutic ablation treatment for cardiac arrhythmia. 

  

	2.	Products – means the Devices and accessories described in Exhibits A and B. 

  

	3.	Enable Technology – means that portion of Enable’s intellectual property rights, designs, know-how, trade secrets, patents, patent rights, and/or inventions that it
actually utilizes in the provision of its services hereunder. 

  

	4.	AtriCure Technology – means the intellectual property rights, designs, know-how, trade secrets, patents, patent rights, inventions and other rights of, used by or
claimed by AtriCure to, under or in connection with the AtriCure Generators or the Handpieces. 

  

	5.	Product Specifications – means written specifications, technical information, drawings, and quality standards agreed to by both Enable and AtriCure, in writing, relating
to the design, development and manufacture of Products. 

  

	6.	Point of Shipment – means Enable’s main facility located in West Chester, Ohio. 

  

	7.	Joint Technology – means the intellectual property rights, designs, know-how, trade secrets, patents, patent rights, and/or inventions made or conceived on and after
January 1, 2002 with material contributions by representatives of both AtriCure and Enable pursuant to this Agreement, exclusive of any Enable Technology or AtriCure Technology. 

  

	8.	Saleable Release – means Enable and AtriCure have approved in writing, Product designs and manufacturing processes to produce Devices for commercial distribution.

  

	9.	Concept/Feasibility Phase – means a phase in the product development cycle that is focused or proving the efficacy of device concepts by building prototypes and models
for bench testing, animal testing and clinical evaluations. 

  

	10.	Year 1 – means February 1, 2003 to January 31, 2004. 

  

	11.	Year 2 – means February 1, 2004 to January 31, 2005. 

  

					
	 EMC-ATR Agreement March 24, 2003-2
	  	2	  	 

 Engagement; Collaboration 
  

	1.	AtriCure hereby engages Enable, and Enable hereby accepts such engagement, to provide the development and manufacturing services for AtriCure as set forth in, and subject to the
terms and conditions of this Agreement. 

  

	2.	This Agreement is to become effective as of February 1, 2003 and shall remain in effect until January 31, 2005. This Agreement may be renewed for additional one year periods beyond
January 31, 2005 solely upon written agreement by AtriCure and Enable on or before October 30, 2004. All fees, schedules and pricing referred to in this Agreement are for Year 1. Year 2 fees, schedules and pricing will be determined for Year 2 by
January 1, 2004 unless noted otherwise. 

  

	3.	The provisions of this Agreement supercede any conflicting provisions of any other Agreement between AtriCure and Enable with respect to the subject matter hereof and of any
purchase order delivered hereunder. In the event of any conflict between the provisions of this Agreement and the Exhibits hereto, the provisions of this Agreement shall govern and control. 

  

	4.	AtriCure hereby represents and warrants that it owns or has the rights to use all of the AtriCure Technology and that the same does not infringe any rights of any third party.

  

	5.	Enable hereby represents and warrants that it owns or has the rights to use all of the Enable Technology and that the same does not infringe any rights of any third party.

  

	6.	Notwithstanding anything herein to the contrary, (i) AtriCure hereby acknowledges that it has no ownership interest in, and shall not by virtue of this Agreement be deemed to have
or obtain any ownership interest in, the Enable Technology or any portion(s) thereof or any improvements thereto, all of which shall be and remain the property of Enable and (ii) Enable hereby acknowledges that it has no ownership interest in, and
shall not by virtue of this Agreement be deemed to have or obtain any ownership interest in, the AtriCure Technology or any portion(s) thereof or any improvements thereto, all of which shall be and remain the property of AtriCure.

  

	7.	Subject to the terms, conditions and limitations set forth herein, each Party shall have an undivided one-half interest in all Joint Technology only outside of the Field of Use.
Notwithstanding the joint ownership of the Joint Technology outside of the Field of Use, and except as may be expressly set forth in this Agreement, neither Party shall have the obligation to account to the other Party for any further development,
distribution, commercialization or other use of the Joint Technology outside of the Field of Use. 

  

	8.	 Within the field of Use Enable agrees to and hereby does grant to AtriCure a perpetual, world-wide, royalty-free, irrevocable, exclusive, transferable license to
make, have made, manufacture, modify, offer for sale, sell and use any and all of 

  

					
	 EMC-ATR Agreement March 24, 2003-2
	  	3	  	 

	 	 
the Joint Technology contributed or owned by Enable. Further, within the Field of Use Enable agrees that it may not: (a) use the Joint Technology for any
purpose other than as contemplated by this Agreement; (b) exploit the Joint Technology for the benefit of any person or entity other than AtriCure; or (c) license or otherwise transfer any of its rights to the Joint Technology in any manner which is
inconsistent with the terms of this Agreement. 

  

	9.	During the term of this Agreement, AtriCure hereby grants Enable a world-wide, royalty-free, non-exclusive, non-transferable license to use and make the AtriCure Technology as
necessary or appropriate for Enable to perform its services hereunder. 

  

	10.	During the term of this Agreement, Enable hereby grants to AtriCure a world-wide, royalty-free, irrevocable, exclusive, transferable license to make, have made, manufacture, offer
for sale, sell and use the Enable Technology solely in the Field of Use. Upon the termination or expiration of this Agreement, unless this Agreement shall have been terminated by Enable as a result of an uncured material breach by AtriCure, the
foregoing license shall automatically and without any further action required by any Party, become perpetual in the Field of Use. 

  

	11.	Each Party hereby agrees to promptly take such further actions and execute and deliver such further instruments and documents as may be necessary or appropriate to more fully
effectuate the transactions provided for in this Agreement. 

  

	12.	Each Party hereby represents and warrants to the other Party that it is not under any obligation, restriction or limitation, contractual or otherwise, to or in favor of any other
individual or entity, which would in any way prohibit or impede it from entering into or performing its duties and responsibilities hereunder. 

  

	13.	Each Party shall cooperate to facilitate the other Party’s performance of all of its services hereunder. 

  

	14.	The provisions of paragraphs 3., 4., 5., 6. 7., 8., 10., 11., 12. above and this paragraph 14, shall survive the expiration or termination of this Agreement.

  

	15.	 ENABLE, for itself and on behalf of its shareholders and affiliates, agrees that ATRICURE shall be entitled to rights of first refusal over any proposed sale or
assignment of any controlling interest in the shares of ENABLE or any proposed sale, assignment or license of any of its material assets. In the event that at any during the term, ENABLE, its affiliates or shareholders shall propose to enter into
any binding commitment for the sale of a controlling interest in the share capital of ENABLE or for the sale, assignment or license of any material assets of ENABLE (a “Proposed Transaction”), then ENABLE shall notify ATRICURE of its
intention to enter into such Proposed Transaction and shall advise ATRICURE of the material terms and conditions of such Proposed Transaction. ATRICURE shall have a period of sixty (60) days from the date of 

  

					
	 EMC-ATR Agreement March 24, 2003-2
	  	4	  	 

	 	 
receipt of any notice of a Proposed Transaction from ENABLE to exercise its rights under this agreement to acquire such controlling interest in ENABLE or
material assets of ENABLE on substantially the same terms as the Proposed Transaction. In the event that ATRICURE shall not elect to exercise its rights of first refusal under this agreement with respect to a Proposed Transaction, then ENABLE shall
be entitled to complete the Proposed Transaction with a party other than ATRICURE on substantially the same terms as were described to ATRICURE in the notice of the Proposed Transaction delivered by ENABLE. 

  
 Development Services 
  

	1.	Development services include the following Enable capabilities: 

  

	 	(a)	Building of prototypes and functional models. 

  

	 	(b)	Design engineering and CAD support. 

  

	 	(c)	Design and building of custom manufacturing equipment, fixtures, tooling, and gages. 

  

	 	(d)	Validation of manufacturing processes. 

  

	 	(e)	Research, start-up, and qualification of supplier processes. 

  

	 	(f)	Mechanical and electrical testing of materials. 

  

	2.	Enable shall provide the development services for the Products as required under Exhibits A, hereto, and during Year 1, AtriCure shall pay Enable a monthly fee of $96,000 (such
monthly fee being sometimes hereinafter referred to as a “Capitalized term”) for such product development services. The capitalized term applies to development services as supplied by Enable employees and on-site contractors for the total
monthly hours, as set forth in Exhibit C. 

  

	3.	Enable shall provide development services for new device concepts that are in the Concept/Feasibility Phase. Such services are included in the capitalized term and the scope of such
services shall not be extended beyond the Concept/Feasibility phase for those Devices not set forth in Exhibit A. 

  

	4.	Enable shall be granted the right of first refusal to develop AtriCure disposable devices for Saleable Release during the term of this agreement, except under change of control,
products which are outside the scope of Enables core competencies, and the 25% of hand piece purchases which are undetermined in year two of the agreement as referenced in the Manufacturing and Supply Section, page 6 paragraph 5.

  

	5.	AtriCure shall reimburse Enable for the following costs that are not inclusive to the capitalized term. Costs shall not exceed $[*] for Year 1 of the agreement.

  

	 	(a)	Hourly employee time charged to the projects, as set forth in exhibit A, prior to Saleable release, will be invoiced at the rates set forth in Exhibit D. 

 

	[*]	Certain information on this page has been omitted and filed separately with the Securities and Exchange Commission. Confidential treatment has been requested with respect to the
omitted portions. 

  

					
	 EMC-ATR Agreement March 24, 2003-2
	  	5	  	 

	 	(b)	Salary exempt and non-exempt employee time charged to the projects that exceed the total monthly hours as set forth in exhibit C, will be invoiced at the rates set forth in Exhibit
D. 

  

	 	(c)	AtriCure Product Development shall pre-approve all billable overtime. 

  

	6.	AtriCure shall reimburse Enable for the following costs that are incurred during the completion of development services. Costs shall not exceed $[*] for Year 1 of the agreement.
Enable will invoice AtriCure at actual plus any shipping and handling charges. 

  

	 	(a)	Prior to Saleable Release, all materials, finished components, and indirect manufacturing materials used to qualify manufacturing processes, validate product designs, and qualify
supplier processes. 

  

	 	(b)	Materials and outside services used by Enable to design, prototype, build, install and qualify manufacturing equipment, fixtures, and gages. 

  

	7.	AtriCure total cost for all referenced and planned projects, that are directly reimbursed to Enable under paragraphs 5. and 6., excluding the fixed “Capitalized term” fee,
shall not exceed a total cost of $[*] during the Year 1 of this agreement. 

  

	8.	AtriCure will be responsible for, at its own cost and expense: 

  

	 	(a)	Tooling, gages, and fixtures used in the manufacture of components and subassemblies that reside at suppliers other than Enable. 

  

	 	(b)	Off-the-shelf assembly and inspection equipment that supports the manufacture of AtriCure products, as set forth in Exhibit B. 

  

	 	(c)	Items classified under paragraphs (a) and (b) are budgeted not to exceed $[*] during Year 1 of the agreement. 

  

	9.	Enable will do everything within reasonable means to complete development services to meet AtriCure project milestones. Enable will notify AtriCure if requests for development
services conflict or exceed Enable’s engineering capacity to complete services by requested due dates. 

  

	[*]	Certain information on this page has been omitted and filed separately with the Securities and Exchange Commission. Confidential treatment has been requested with respect to the
omitted portions. 

  
  

					
	 EMC-ATR Agreement March 24, 2003-2
	  	6	  	 

	11.	AtriCure will be responsible, at its own cost and expense, for the development, testing, maintenance and content of the Product Specifications for the Products.

  

	12.	AtriCure will be responsible for, at its own cost and expense (except as described in clause (k) below): 

  

	 	(a)	Design and development of the Products, except for those service described by paragraph 1. 

  

	 	(b)	Clinical testing of prototypes of Products, except for those service described by paragraph 1. 

  

	 	(c)	Attaining the domestic regulatory approvals, and any foreign regulatory approvals, required to test, market, sell and, if applicable, export, each Product. 

 

	 	(d)	Attaining CE Mark. 

  

	 	(e)	The ongoing warehousing of finished Product. 

  

	 	(f)	The content of labeling, packaging, warranty documentation, instructions for use, shipping, and traccability of Product to customers and retailers. 

  

	 	(g)	The start-up and validation of any sterilization vendor for AtriCure Devices. 

  

	 	(h)	The annual re-validation and/or certification of sterilization processes for AtriCure Devices. 

  

	 	(i)	The filing, prosecution, maintenance, and enforcement of any and all patent applications and patents covering all or any portion of the AtriCure Technology, and in certain
circumstances as set forth in paragraph 11 below, the Joint Technology. 

  

	 	(j)	The worldwide marketing, sales and distribution of Products under programs to the extent established by AtriCure. 

  

	 	(k)	Cooperating with Enable in the enforcement of intellectual property rights owned by Enable in the Enable Technology, as such effect the Products or Joint Technology in the Field of
Use, provided that all expenses, including without limitation, legal and witness fees and related costs thereof, are paid or reimbursed by Enable. 

  

	9.	Included in development services and covered under the capitalized term, Enable will: 

  

	 	(a)	Assist AtriCure with the design and development of Products. 

  

					
	 EMC-ATR Agreement March 24, 2003-2
	  	7	  	 

	 	(b)	Assist AtriCure with the domestic regulatory approvals as required to market each Product. 

  

	 	(c)	Assist AtriCure with the clinical testing of prototypes of Products. 

  

	 	(d)	File, prosecute, maintain, and enforce patent applications and patents covering Enable Technology and in certain circumstance as set forth in paragraph 11 below, the Joint
Technology. 

  

	 	(e)	Cooperate with AtriCure in the filing of patents and the enforcement of AtriCure Technology and Joint Technology, provided that all expenses, including without limitation, legal and
witness fees and related costs thereof, are paid or reimbursed by AtriCure. 

  

	10.	Capitalized term payments are due the 15th day
of each month. Terms of payment for development services, not included in the Capitalized term, and materials are net thirty (30) days. 

  

	11.	AtriCure shall have the exclusive first right to file an application for patent protection of any Joint Technology. In the event that: (i) AtriCure has either not filed an
application for patent protection with respect to a particular piece of Joint Technology in at least one jurisdiction or has not notified Enable in writing of AtriCure’s intent to so file; and (ii) the allowable time to file such an application
in the United States will expire within sixty (60) calendar days, pursuant to applicable law, then Enable shall have the exclusive right to file a patent application with respect to such Joint Technology by giving AtriCure written notice of
Enable’s intent. The Parties shall reasonably cooperate with each other in these activities, including the preparation and filing of assignment documents that identify both Parties as assignees of the relevant Joint Technology. The Party which
has filed a Joint Technology patent (the “Filing Party”) shall have primary responsibility for the maintenance of such patent with the applicable government patent office or agency, including the payment of all associated
fees to such office or agency. During and from time to time after the prosecution of any such patent, the Filing Party shall send to the other Party a copy of all notifications and correspondence from the applicable government patent office or
agency with respect to such patent. Such notifications shall include but not be limited to schedules of anticipated maintenance and related payments. In the event the Filing Party does not desire to continue the patent prosecution process with
respect to any such patent or does not make, or states in writing that it does not intend to make, any required payment with respect to the filing process or maintenance of such patent (in either case, the “Abandoned Patent”)
(and, in such event, such Party shall be deemed the “Abandoning Party” for purposes of this paragraph), the other Party may continue the prosecution process and make all required payments for such patent. In such event, the
Abandoning Party will assign and does hereby irrevocably assign to the other Party all right, title and interest in and to the Abandoned Patent. 

  

					
	 EMC-ATR Agreement March 24, 2003-2
	  	8	  	 

	10.	AtriCure and Enable will conduct project meetings to review milestones, deliverables, and priorities. 

  

	12.	AtriCure shall have an exclusive right of first refusal to enforce the Joint Technology. In the event that AtriCure does not send written notice of AtriCure’s intent to enforce
a particular piece of Joint Technology within thirty (30) calendar days of AtriCure’s having notice of the need for such enforcement (the “AtriCure Notice Period”), Enable shall have the exclusive right to bring such an
enforcement action. Such exclusive right of Enable shall expire unless Enable shall have commenced an enforcement action within thirty (30) calendar days after the AtriCure Notice Period. Each Party agrees to and hereby grants the other Party its
consent to bring such enforcement actions consistent with this paragraph 8. In the event such consent is unreasonably withheld or delayed each Party (the “Appointing Party”) hereby irrevocably designates and appoints the
other Party (the “Designated Party”) as the Appointing Party’s agent and attorney-in-fact, to act for and in the Appointing Party’s behalf and stead, for the limited purpose of executing and filing any such document
and doing all other lawfully permitted acts to further enforcement of Joint Technology with the same force and effect as if executed and delivered by the Appointing Party. To the extent that either Party elects to enforce any Joint Technology and
the other Party has expenses (including attorneys’ fees) as a result of such enforcement, the Party enforcing such Joint Technology shall pay all such expenses for the other Party. The Party which has elected to enforce the Joint Technology
shall be entitled to recover all of its costs of enforcement, including those paid on behalf of the other Party, from any monetary judgment awarded to it or settlement reached pursuant to such enforcement. 

  

	13.	The provisions of paragraphs 11. and 12. above and this paragraph 13. shall survive the expiration or termination of this Agreement. 

  
 Manufacturing and Supply 
  

	1.	Enable shall manufacture all Products strictly in accordance with the Product Specifications applicable to such Products. Enable shall promptly notify AtriCure in writing of any
suggested changes to the Product Specifications or any validated changes to the manufacturing process prior to shipment of the Products. 

  

	2.	On or before the thirtieth (30th) day preceding the beginning of each calendar quarter, AtriCure will provide Enable with a rolling four (4) quarter forecast of the volume of
Products to be purchased by AtriCure during such quarter and the three (3) next successive calendar quarters. Such forecast may not reflect for any quarter an increase or decrease in the volume of Products to be purchased (on a Product-by-Product
basis) of more than [*]% from the immediately preceding forecast. Nevertheless, Enable may, at its option, determine to use its commercially reasonable efforts to supply any forecast which does exceed such [*]% threshold, in which case any added
cost or expense incurred in connection shall be borne by AtriCure. The forecast for the quarter following the quarter in which notice is given shall specify requested delivery dates and quantities to be delivered on such dates.

  

	[*]	Certain information on this page has been omitted and filed separately with the Securities and Exchange Commission. Confidential treatment has been requested with respect to the
omitted portions. 

  
  

					
	 EMC-ATR Agreement March 24, 2003-2
	  	9	  	 

	3.	On the thirtieth (30th) day preceding the beginning of each calendar quarter, such forecast shall become firm (i.e., become and be deemed a binding purchase order) for such
quarter for the quantities of Products set forth in the latest forecast given by AtriCure to Enable hereunder. 

  

	4.	Enable agrees to ship via AtriCure’s reasonably designated carrier. AtriCure may specify individual delivery dates and quantities following these guidelines; (a) AtriCure may
not make any applicable adjustments to any delivery date within sixty (60) days of such delivery date without Enable’s prior written approval, (b) AtriCure may not accelerate any delivery date by more than thirty (30) days from the original
date without Enable’s prior written approval, and (c) AtriCure may increase scheduled delivery quantities (subject to the other provisions of this Agreement) only upon forty-five (45) days’ prior written notice, or with shorter notice with
Enable’s prior written approval. Nevertheless, Enable may, at its option, determine to use its commercially reasonable efforts to deliver Products timely if a request is made for a shorter period, with any added cost or expense incurred in
connection therewith to be borne by AtriCure. 

  

	5.	AtriCure shall purchase all of its requirements outlined in Exhibit A for disposable devices only from Enable during Year 1 of this Agreement. AtriCure agrees to purchase a minimum
of 75% of the total hand-piece volume of Saleable Release disposable devices from Enable during Year 2 of the agreement. 

  

	6.	AtriCure shall be obligated to purchase Products at the volume-based prices set forth in Exhibit B for the first 8 mouths of Year 1. Product prices will be recalculated to reflect
actual manufacturing costs and adjusted volumes in the 8th month of Year 1 and every 6 months thereafter for the
term of the Agreement. Any change in pricing will be effective in the month following the price adjustments. Pricing cannot increase more than [*] ([*]%) percent at each review cycle without mutual agreement between Enable and AtriCure. Selling
prices will target Enable maintaining a [*]% gross profit margin. 

  

	7.	Products will be shipped directly from the sterilizer to AtriCure and will be quarantined by AtriCure until inspected and released by Enable. AtriCure shall provide adequate
controls to prevent tampering or damage to Products waiting inspection. Products will be deemed released when the certificate of conformance and invoice are delivered to AtriCure. At the time of release, title and risk of loss shall pass to
AtriCure. 

  

	8.	The per-unit price, exclusive of all taxes, duties, imports, costs, charges (including shipping and insurance charges) and expenses of any nature and regardless of by which
jurisdiction imposed or by which entity charged, to be paid by AtriCure for the Products that are delivered by Enable are set forth opposite the respective Products on Exhibit B hereto. Such prices shall be the total price charged by Enable to
AtriCure (including shipping and insurance charges for Products shipped from Enable to the sterilizer and from the sterilizer to AtriCure) and shall remain firm and unchanged during the term of this Agreement, except as may be

  

	[*]	Certain information on this page has been omitted and filed separately with the Securities and Exchange Commission. Confidential treatment has been requested with respect to the
omitted portions. 

  
  

					
	 EMC-ATR Agreement March 24, 2003-2
	  	10	  	 

	 	 
mutually agreed upon by the Parties in writing. AtriCure shall also pay any and all sales or similar taxes, if any (other than taxes imposed on Enable’s
net income), and all duties and shipping charges incurred, in the sale and delivery of Products to AtriCure. Enable agrees to reasonably cooperate in obtaining any applicable resale or other exemptions for sales or similar taxes applicable to the
sale and delivery of Products by Enable to AtriCure hereunder. 

  

	9.	Equipment, tooling and fixtures that are solely funded hereunder by AtriCure and used for the manufacture of the Devices will be the sole property of AtriCure.

  

	10.	Equipment, tooling and fixtures that are solely funded by Enable or owned by Enable prior to January 1, 2002 and used for the manufacture of the Devices will be the sole
property of Enable. 

  

	11.	Enable shall submit an invoice to AtriCure with each released shipment of Products ordered by AtriCure, Each invoice shall be due and payable net thirty (30) days from the date of
invoice of Products from Enable. 

  

	12.	AtriCure undertakes to begin the regular commercial sale of the Products as soon as commercially reasonable and thereafter, during the term of this Agreement, to use reasonable
commercial efforts to continue such production and sale diligently. 

  

	13.	AtriCure shall be responsible for handling and processing any and all customer complaints. 

  

	14.	The provisions of paragraphs 9., 10., 13., and this paragraph 14. shall survive the expiration or termination of this Agreement. 

  

	15.	Product design changes that increase manufacturing costs, after Saleable Release, will be added to the selling price for product produced after implementation. All costs associated
with such product design changes, including tooling, equipment, fixtures, gages, documentation, validation, administrative support, and materials, will be AtriCure’s responsibility. 

  

	16.	All manufacturing process changes must be approved by AtriCure. Any changes that reduce the manufacturing costs and have been paid for by AtriCure and result in lower manufacturing
costs will be included in the selling price. Any changes that reduce manufacturing costs and have been funded by Enable will not be included in the selling price. Any changes jointly funded by AtriCure and Enable will be shared by both companies.

  

	17.	Enable shall maintain compliance with the US FDA Quality System Regulations and EN/ISO 13485 or EN/ISO 13488. Enable shall retain the required quality records related to these
standards to demonstrate compliance of the development and manufacture of AtriCure products to these standards. AtriCure shall receive copies of any correspondence with outside regulatory agencies that might affect AtriCure regulatory status.

  

					
	 EMC-ATR Agreement March 24, 2003-2
	  	11	  	 

	18.	Enable shall establish and follow failure analysis and corrective/preventative action procedures for AtriCure returned products and complaints. Enable shall provide written
corrective/preventative action response to returned products and complaints within 30 days. A service or a complaint record will accompany any required product returned to AtriCure. Events that are deemed by AtriCure to require a medical device
report to the US FDA or an incident report under the European or Canadian Medical Device Vigilance System will be investigated by Enable and a report made to AtriCure within 72 hours of receipt by Enable of the reported event to allow AtriCure to
respond the proper regulatory agencies. 

  

	19.	Enable is responsible for developing a Device History Record for each batch of AtriCure product and to maintain component inspection and trace-ability records.

  

	20.	AtriCure and Enable will identify [he key Device Master Record documents and Enable will be required to forward copies of all changes to the identified DMR documents to AtriCure. In
addition, changes to the following documents require approval in writing by AtriCure prior to Enable implementation: device specifications and device labeling (including Instructions For Use). 

  

	21.	Prior to transfer to manufacturing of any new product or process, AtriCure and Enable may jointly develop and release an acceptance test procedure for use by either company.

  

	22.	Enable shall provide documents and/or reports as referenced in AtriCure internal design control procedure to AtriCure for regulatory purposes. 

  

	23.	Enable shall allow reasonable access to AtriCure, AtriCure notified body and the US FDA lo facilities and records to conduct an audit or other reasonable business purpose. Others
will be allowed access for auditing purposes if mutually agreed to by AtriCure and Enable. AtriCure shall be allowed to audit at a frequency of not less than once per year. Enable shall provide written corrective action response to AtriCure within
30 days of notification of findings. 

  

	24.	AtriCure shall notify Enable 6 months prior to ceasing distribution of any Saleable Release Device. AtriCure shall reimburse Enable for all materials in inventory, in-process,
and/or at suppliers that cannot be built into Saleable devices as a result of the stoppage of production. AtriCure shall reimburse Enable for all outstanding orders that cannot be closed or reconciled prior to the ceasing of production.

  
 Use of Certain Enable Facilities, Software, and Equipment

  

	1.	During the term of this Agreement, AtriCure shall have the following limited use of certain Enable facilities and equipment therefor: one AtriCure employee shall be granted
reasonable non-exclusive access during normal business hours (provided that the same does not interfere with the conduct of Enable’s business) to: 

  

	 	(a)	80 square feet of cubicle office space; 

  

					
	 EMC-ATR Agreement March 24, 2003-2
	  	12	  	 

	 	(b)	One workbench in the model shop area; and 

  

	 	(c)	Use of model shop equipment. 

  
 Warranties, Limitations of Liability, Indemnification 
  

	1.	Enable hereby represents and warrants that each Product sold by Enable to AtriCure hereunder shall: (i) be in accordance with the Product Specifications; and (ii) not have any
defects in materials or workmanship for a period equal to the shelf life of the product, starting the date that Enable ships such Product to AtriCure. Upon written notification and receipt of a defective Product during the aforementioned warranty
period, Enable’s obligation shall be limited to the repair or replacement of the defective Product at no cost to Atricure or any Atricure customer. 

  

	2.	EXCEPT AS EXPRESSLY OTHERWISE SET FORTH HEREIN, ENABLE MAKES NO REPRESENTATIONS OR WARRANTIES OF ANY KIND, WHETHER EXPRESS OR IMPLIED, WITH RESPECT TO THIS AGREEMENT, THE ENABLE
TECHNOLOGY, OR ANY SERVICES, GOODS OR DEVELOPMENTS TO BE PROVIDED IN CONNECTION WITH THIS AGREEMENT, INCLUDING, BUT NOT LIMITED TO, THE IMPLIED WARRANTIES OF MERCHANTABILITY OR FITNESS FOR A PARTICULAR PURPOSE OR DESCRIPTION, OR THE ABSENCE OF
INFRINGEMENT UPON ANY THIRD PARTY’S INTELLECTUAL PROPERTY RIGHTS. 

  
 IN NO EVENT SHALL EITHER PARTY BE LIABLE TO THE OTHER PARTY FOR ANY SPECIAL, INDIRECT, INCIDENTAL, CONSEQUENTIAL OR EXEMPLARY DAMAGES ARISING OUT OF, PURSUANT TO OR IN CONNECTION WITH THIS AGREEMENT, INCLUDING, BUT
NOT LIMITED TO, LOSS OF PROFIT OR OTHER MONETARY LOSS, EVEN IF THE FIRST PARTY IS ADVISED IN WRITING IN ADVANCE BY THE OTHER PARTY OF THE POSSIBILITY OF SUCH DAMAGES. NOTWITHSTANDING ANYTHING IN THIS AGREEMENT TO THE CONTRARY, EACH PARTY’S
LIABILITY FOR DAMAGES TO THE OTHER PARTY FOR ANY CAUSE OR CAUSES OF ACTION WHATSOEVER (EXCLUDING ANY CAUSE OF ACTION ARISING FROM A THIRD PARTY CLAIM), AND REGARDLESS OF FORM, WHETHER IN CONTRACT OR IN TORT (INCLUDING NEGLIGENCE), OR OTHERWISE,
SHALL IN NO EVENT EXCEED $100,000. 
  

	3.	 AtriCure shall defend, indemnify and hold harmless Enable from and against any and all losses, damages, liabilities, settlements, costs and expenses (including
attorneys’ fees, expenses of other professionals and amounts owed or paid as indemnification obligations to third parties, including shareholders) as incurred, 

  

					
	 EMC-ATR Agreement March 24, 2003-2
	  	13	  	 

	 	 
from third party claims arising out of or resulting from: (i) the Product Specifications; (ii) product liability arising out of the Products (except in the
event such product liability is a result of any action on the part of Enable, excluding any such action taken pursuant to AtriCure’s specific instruction); (iii) intellectual property infringement or misappropriation arising out of the Atricure
Technology and any contributions made by AtriCure to the Joint Technology; and (iv) failure of AtriCure to conduct sales and shipment of the Products in accordance with all applicable law (except for any such failure which arises out of any breach
or misrepresentation by Enable hereunder). 

  

	4.	Enable shall defend, indemnify and hold harmless AtriCure from and against any and all losses, damages, liabilities, settlements, costs and expenses (including attorneys’ fees,
expenses of other professionals and amounts owed or paid as indemnification obligations to third parties, including shareholders) as incurred, from third party claims arising out of or resulting from: (i) performing its obligations not in accordance
with the Product Specifications; (ii) product liability arising out of any Product attributable to any action on the part of Enable (except in the event such product liability is a result of action taken pursuant to AtriCure’s specific
instruction); (iii) intellectual property infringement or misappropriation arising out of the Enable Technology or any contributions made by Enable to the Joint Technology; and (iv) breach of the Product warranties given by Enable under paragraph 1.
above. 

  

	5.	Neither Party as the indemnifying Party (the “Indemnitor”) shall have any obligation under paragraphs 3, and 4, above to the extent any claim results from: (i) any use of
the Indemnitor’s contribution in breach of this Agreement; or (ii) any alteration or modification of the Indemnitor’s contribution hereunder not provided or authorized in writing by the Indemnitor, if the claim would not have arisen but
for such alteration or modification. 

  

	6.	 Each Party entitled to indemnification hereunder (the “Indemnitee”) shall give prompt notice (the “Indemnity Notice”) to the Indemnitor of the
institution of any claims, actions, audits, investigations, suits, proceedings or demands at any time instituted or made, in connection with which the Indemnitee would be, or would be reasonably likely to be, entitled to claim indemnification under
Sections 3 and 4 above from the Indemnitor. The Indemnitor shall, at its option within fifteen (15) days after receiving the Indemnity Notice and at its own cost and expense, have full authority to defend, adjust, compromise or settle any such
claim, action, suit, proceeding or demand, in the name of the Indemnitee or otherwise as the Indemnitor shall elect; provided, however, that the Indemnitor shall not consent to the entry of any judgment or enter into any settlement,
except with the written consent of the Indemnitee, which shall not unreasonably be withheld. As to any claim the defense of which has been assumed by the Indemnitor, (i) the Indemnitee shall cooperate fully in such defense as and to the extent
reasonably requested by the Indemnitor (such cooperation shall include the retention and, upon the Indemnitor’s request, the provision to the Indemnitor of records and information which are reasonably relevant to such claim or demand and making

  

					
	 EMC-ATR Agreement March 24, 2003-2
	  	14	  	 

	 	 
employees available on a mutually convenient basis to provide additional information and explanation of any material provided hereunder) and (ii) the
Indemnitor shall not, subsequent to such assumption, be liable for any costs and expenses (including attorneys’ fees) incurred by the Indemnitee. As to any claim the defense of which has been assumed by the Indemnitee, (i) the Indemnitor shall
cooperate fully in such defense as and to the extent reasonably requested by the Indemnitee (such cooperation shall include the retention and, upon the Indemnitee’s request, the provision to the Indemnitee of records and information which are
reasonably relevant to such claim or demand and making employees available on a mutually convenient basis lo provide additional information and explanation of any material provided hereunder) and (ii) the Indemnitor shall, subsequent to such
assumption, be liable for any costs and expenses (including reasonable attorneys’ fees) incurred by the Indemnitee. 

  

	7.	The provisions of paragraphs 1. through 6. above and this paragraph 7, shall survive the expiration or termination of this Agreement. 

  
 Confidentiality 
  

	1.	Each Party agrees to keep confidential and not disclose to any third party any of the confidential or proprietary information of the other Party (i) which has not been disclosed
publicly by the disclosing Party, (ii) which is otherwise not a matter of public knowledge or (iii) which is a matter of public knowledge but the receiving Party knows or has reason to know that such information became a matter of public knowledge
through an unauthorized disclosure. The terms “confidential or proprietary information” shall include all information the unauthorized disclosure or use of which would reduce the value of such information to the disclosing Party including,
without limitation, the disclosing Party’s trade secrets, know-how, intellectual property rights, technology, practices and processes. 

  

	2.	Neither Party shall use confidential or proprietary information of the other Party for any purpose other than the purposes specified in this Agreement. 

  

	3.	Each Party may disclose confidential or proprietary information of the other Party to its employees and bona fide agents, provided that the receiving Party shall remain
liable for any unauthorized disclosures by its employees and bona fide agents of the disclosing Party’s confidential or proprietary information. 

  

	4.	Upon the written request of the disclosing Party, the receiving Party shall return all tangible materials, records and documents (including those that are electronically stored)
that contain confidential or proprietary information of the disclosing Party. 

  

	5.	 Each Party acknowledges that any breach by it of its obligations set forth in paragraphs 1. through 4. above will result in irreparable injury to the other Party
for which money damages could not adequately compensate. In the event of a 

  

					
	 EMC-ATR Agreement March 24, 2003-2
	  	15	  	 

	 	 
breach by the receiving Party of any such obligations, the disclosing Party shall be entitled, in addition to all other rights and remedies which it may have
at law or in equity, to seek an injunction by any competent court enjoining and restraining the receiving Party and all other persons involved therein from continuing such breach. 

  

	6.	The provisions of paragraphs 1, through 5, above and this paragraph 6, shall survive the expiration or termination of this Agreement. 

  
 Force Majeure 
  
 Neither Party shall be held to be in breach or default of any of its obligations under this Agreement, or liable for any
loss, damages or delay, if and to the extent caused by any acts of war, terrorism, government or military acts, orders or restrictions, flood, fire, earthquake, strikes, lockouts or other labor disputes, failure of suppliers, acts of God or any
other cause beyond its reasonable control, provided that any such delay shall be for the shortest period of time practicable. 
  
 Notice of Breach 
  
 Each Party shall provide prior written notice to the other Party of any claimed breach or default hereunder, whereupon the Party alleged to be in breach
or default shall be afforded a thirty (30) day opportunity to cure. In the event that either Party has not cured a material breach in such thirty (30) day period, the other Party shall be entitled to terminate this Agreement immediately upon written
notice. 
  
 Independent Contractor Status 
  
 The Parties agree that the relationship between Enable and AtriCure is that
of independent contractors. No joint venture, partnership, relationship of principal and agent, employer and employee or other similar relationship is formed by this Agreement, and neither Party shall have any authority to bind the other.

  
 Assignment; Binding Effect 
  
 This Agreement and the rights and obligations of the Parties are personal in
nature and may not be assigned without the other Party’s prior written consent, except (i) in connection with a sale or transfer of all or substantially all of the business or assets of the assigning Party pertaining to the subject matter
hereof, whether by merger, reorganization, acquisition, sale of assets or otherwise, and (ii) nothing herein shall operate to prevent or limit Enable from subcontracting out any of its obligations hereunder provided that Enable remains responsible
for the fulfillment of its obligations as provided herein. Any attempted or purported assignment in violation of the foregoing shall be deemed null and void and without effect. This Agreement shall inure to the benefit of, and shall be binding upon,
the Parties and 

  

					
	 EMC-ATR Agreement March 24, 2003-2
	  	16	  	 

 
their respective successors and permitted assigns. This paragraph shall survive the expiration or termination of this Agreement. 
  
 Governing Law; Dispute Resolution 
  
 This Agreement shall be governed by, and construed and enforced in
accordance with, the laws of the State of Ohio applicable to contracts made and to be performed entirely therein (without giving effect to its conflict of laws rules). In the event of a claim or dispute between the Parties to this Agreement, the
Parties agree to promptly meet and confer with the goal of settling such dispute or claim. If the Parties are unable to reach an amicable agreement concerning such dispute or claim within thirty (30) days, the Parties agree to submit the matter to
binding arbitration, in the State of Ohio, by and in accordance with the commercial arbitration rules of the American Arbitration Association, and judgment upon the award rendered by the arbitrators may be entered in any court having jurisdiction
thereof; provided, however, that nothing in this paragraph shall prevent either Party from seeking injunctive or other equitable relief by any competent court to which such Party may be entitled hereunder or under applicable law. This
paragraph shall survive the expiration or termination of this Agreement. 
  
 Entire Agreement 
  
 This Agreement (inclusive of
the Exhibits hereto) constitutes the entire understanding and agreement between the Parties respecting the subject matter hereof, and there are no representations, warranties or commitments which may be relied upon by either Party with respect
thereto except as specifically set forth in this Agreement. This Agreement (inclusive of the Exhibits hereto) supersedes any and all prior or contemporaneous agreements, commitments, representations, writings, and discussions between AtriCure and
Enable, whether oral or written, with respect to the subject matter hereof, including without limitation, First Amended and Restated Agreement. This Agreement (inclusive of the Exhibits hereto) may be modified, amended or terminated only by an
instrument in writing executed by all of the Parties. This paragraph shall survive the expiration or termination of this Agreement. 
  
 Notices 
  
 Any notice, request, demand or other communication hereunder shall be in writing and shall be deemed to be duly given when delivered by prepaid, registered or certified mail, return receipt requested, personal
delivery, or by nationally recognized, prepaid, receipted overnight courier (such as FedEx). This paragraph shall survive the expiration or termination of this Agreement. 
  
 Savings Clause 
  
 Should any valid federal or state law or final determination of any administrative agency or court of competent jurisdiction invalidate or otherwise
affect any provision of this Agreement, the provision or provisions so affected shall be conformed automatically and to the extent possible to the law or determination in 

  

					
	 EMC-ATR Agreement March 24, 2003-2
	  	17	  	 

 
question, and in all events the remaining provisions of this Agreement shall continue in full force and effect. This paragraph shall survive the expiration
or termination of this Agreement. 
  
 Counterparts 
  
 This Agreement may be executed in counterparts and by facsimile signatures,
each of which shall be deemed to be an original, and all of which shall constitute one and the same instrument. 
  
 No Waiver 
  
 The failure of either Party at any time to require performance by the other Party of any provision hereof shall not affect or limit the full rights to
require such performance at any time thereafter. The waiver by either Party of a breach of any provision hereof shall not be taken, construed or held to be a waiver of any breach thereafter or of any other provision hereof. Any and all waivers
hereunder must be in writing, signed by the Party against whom waiver is sought. 
  
 [remainder of page intentionally left blank] 
  

					
	 EMC-ATR Agreement March 24, 2003-2
	  	18	  	 

 IN WITNESS WHEREOF, the Parties have caused this Agreement to be duly executed as of the first date written above.

  

									
	 ATRICURE, INC.
	 	 	 	 ENABLE MEDICAL CORPORATION

					
	By:	 	 /s/ David Drachman
	 	 	 	By:	 	 /s/ Jon Sherman

	 	 	 David Drachman
	 	 	 	 	 	 Jon Sherman

	 	 	 President and Chief Executive Officer
	 	 	 	 	 	 Vice President of Engineering

			
	 	 	 	 	- and -
					
	 	 	 	 	 	 	By:	 	 /s/ Gregory Drach

	 	 	 	 	 	 	 	 	 Gregory Drach

	 	 	 	 	 	 	 	 	 Chief Operating Officer

  

					
	 EMC-ATR Agreement March 24, 2003-2
	  	19	  	 

 EXHIBIT A 
 Projects 
  
 The following projects will be
Saleable Release Devices and are included in the development services Capitalized term: 
  

	 	1.	LHP2 Device – with enhanced electrode configuration. 

  

	 	2.	LHP3 Device – product extension of LHP2 device with longer jaws and wider jaw opening. 

  

	 	3.	Bipolar Ablating Forcep – new product concept, intended to resemble a standard bipolar forcep with proprietary features added. 

  
 The following projects are included in the Capitalized term, up to and including the
Concept/Feasibility Phase of development: 
  

	 	1.	Prototypes to support a standalone treatment approach. 

  

					
	 EMC-ATR Agreement March 24, 2003-2
	  	20	  	 

 EXHIBIT B 
 Manufactured Products and Pricing Schedule 
  

	1.	The following devices will be manufactured by Enable during Year 1 of this agreement: 

  

	 	1.	LHP2 Handpiece, with and/or without enhanced electrode configuration 

  

	 	2.	LHP3 Handpiece 

  

	 	3.	Bipolar Ablating Forcep 

  

	2.	Selling Prices for quarterly volumes of LHP2 devices are based on Enable maintaining a [*]% gross profit margin. 

  

					
	 Quarterly Volume of
at Least x Devices1

	  	Selling Price per Device
at Given Volume2

	 
	 £900
	  	$	[	*]
	 1050
	  	$	[	*]
	 1200
	  	$	[	*]
	 1350
	  	$	[	*]
	 1500
	  	$	[	*]
	 1650
	  	$	[	*]
	 1800
	  	$	[	*]
	 1950
	  	$	[	*]
	 2100
	  	$	[	*]
	 2250
	  	$	[	*]
	 2400
	  	$	[	*]

  

	1	Quarterly volumes include demonstration units built to LHP2 requirements but exclude special engineering builds. 

  

	2	Selling prices apply to demonstration units built to LHP2 requirements but exclude special engineering builds. 

  
 Additional Terms: 
  

	 	1.	Selling prices for LHP3 and Bipolar Ablating Forcep device have not been determined and are not included in this agreement. At the time of setting selling prices, Enable will set
the selling based upon quarterly volume that includes a [*]% gross profit margin. 

  

	[*]	Certain information on this page has been omitted and filed separately with the Securities and Exchange Commission. Confidential treatment has been requested with respect to the
omitted portions. 

  

					
	 EMC-ATR Agreement March 24, 2003-2
	  	21	  	 

 EXHIBIT C 
 Enable Employees included in Capitalized term with Monthly Total Hours 
  
 The following employees have been calculated into the Capitalized term for the total monthly hours listed. These hours represent the maximum amount of time that is included in the Capitalized term and the minimum
amount of time that each employee will spend supporting AtriCure projects. Time charged to AtriCure projects, as set forth in Exhibit A, that exceed the total monthly hours listed below, will be billed at the rates set forth in Exhibit D.

  

							
	 First Name

	 	 Last Name

	 	 % of Total
Working Hours
per Month1

	 	 Total Monthly
Hours based on
20 Working
Days per
Month

	 [*]
	 	 [*]
	 	50%	 	80
	 [*]
	 	 [*]
	 	100%	 	160
	 [*]
	 	 [*]
	 	10%	 	16
	 [*]
	 	 [*]
	 	100%	 	160
	 [*]
	 	 [*]
	 	100%	 	160
	 [*]
	 	 [*]
	 	100%	 	160
	 [*]
	 	 [*]
	 	100%	 	160
	 [*]
	 	 [*]
	 	100%	 	160
	 [*]
	 	 [*]
	 	60%	 	96
	 [*]
	 	 [*]
	 	50%	 	80
	 [*]
	 	 [*]
	 	25%	 	40
	 [*]
	 	 [*]
	 	100%	 	160

  

	1	Assumes 8 hours per day and Monday through Friday. Excludes Saturday, Sunday and Enable recognized or paid holidays. 

  
 Any Enable employee not listed above is not included in the Capitalized term, except
replacement employees. 
  
 If for any reason, an employee or contractor from the
aforementioned list is terminated, voluntarily or involuntarily, Enable will do everything possible to replace the employee with a permanent employee, temporary employee, or an independent contractor, with the same skill sets, in the shortest amount
of time. 
  

	[*]	Certain information on this page has been omitted and filed separately with the Securities and Exchange Commission. Confidential treatment has been requested with respect to the
omitted portions. 

  

					
	 EMC-ATR Agreement March 24, 2003-2
	  	22	  	 

 EXHIBIT D 
 Billing Rates 
  
 The following billing
rates will be applied to hours not included in the Capitalized term for Year 1. Billing rates for Year 2 will be increased by [*]%. 
  

					
	 First Name

	  	Last Name

	 	Billing Rate

	 [*]
	  	[*]	 	$[*]/hr
	 [*]
	  	[*]	 	$[*]/hr
	 [*]
	  	[*]	 	$[*]/hr
	 [*]
	  	[*]	 	$[*]/hr
	 [*]
	  	[*]	 	$[*]/hr
	 [*]
	  	[*]**	 	OT: $[*]/hr
	 [*]
	  	[*]	 	$[*]/hr
	 [*]
	  	[*]	 	$[*]/hr
	 [*]
	  	[*]	 	$[*]/hr
	 [*]
	  	[*]	 	$[*]/hr
	 [*]
	  	[*]	 	$[*]/hr
	 [*]
	  	[*]	 	$[*]/hr
	 [*]
	  	[*]	 	$[*]/hr
	 Mfg
	  	Engineer	 	$[*]/hr
	 Director
	  	Quality/Operations	 	$[*]/hr
	 Indirect
	  	Mfg and Quality**	 	ST: $[*]/hr*
OT: $[*]/hr*
	 Production
	  	Associates**	 	ST: $[*]/hr*
OT: $[*]/hr*

  

	*	Billing rates are fully burdened. 

  

	**	Non-exempt employee. 

  

	[*]	Certain information on this page has been omitted and filed separately with the Securities and Exchange Commission. Confidential treatment has been requested with respect to the
omitted portions. 

  

					
	 EMC-ATR Agreement March 24, 2003-2
	  	23Technology Transfer Agreement, dated as of 05/25/2001

 Exhibit 10.9 
  
 Confidential treatment has been requested for portions of this exhibit. The copy filed herewith omits the information subject to the
confidentiality request. Omissions are designated as [*]. A complete version of this exhibit has been filed separately with the Securities and Exchange Commission pursuant to Rule 406 of the Securities Act of 1933, as amended. 
  
  
 Technology Transfer Agreement 
 Page 1 
  
 TECHNOLOGY TRANSFER AGREEMENT 
  
 This Technology Transfer Agreement (the “Agreement”) is effective May 25, 2001 (the “Effective Date”) and is between Enable Medical
Corporation, a Delaware Corporation having offices at 6345 Centre Park Drive, West Chester, Ohio 45069 (“Enable”) and AtriCure, Inc., a Delaware Corporation having offices at 6033 Schumacher Park Drive, West Chester, Ohio 45069
(“AtriCure”). 
  
 Background 
  
 Enable owns or controls certain patent applications, which are based upon
inventions made by Michael D. Hooven and/or James A. Chaldekas while employed by Enable, as set forth in the attached Schedule A (the “Enable Patent Rights”). Enable also owns or controls other ideas, concepts, and inventions made by
Michael D. Hooven while employed by Enable, which are recorded in laboratory notebooks, as set forth in the Attached Schedule B (the “Hooven Technology”). Enable further owns or controls other intellectual property in the form of data and
information recorded in physical files, notebooks, log books, computer files, and other materials prepared by other individuals while employed by Enable, which arose in connection with or otherwise relate to the Enable Patent Rights and/or the
Hooven Technology, as set forth in Schedule C (the “Related Materials”). 
  
 AtriCure desires exclusive ownership of the Enable Patent Rights, the Hooven Technology, and the Related Materials to design, develop, manufacture, and sell products and techniques in the conduct of its business
activities. 
  
 Enable also owns or controls certain other
technology and know-how relating to surface preparation and materials deposition systems and techniques, thermal forming/curving systems and techniques, and resistive ink pad printing systems and techniques, as set forth in Schedule D (the
“Enable Technologies”), which are useful or prospectively useful in the design, development and use of products and techniques by AtriCure to treat heart disease or disorders. 
  
 AtriCure desires access to the Enable Technologies to design, develop, manufacture, and sell products and techniques to
treat heart disease or disorders. 
  
 Accordingly, the parties
agree as follows: 
  
 Article 1. Definition of Terms

  
 1.1. The term “Atricure” shall include “Affiliates.”
The term “Affiliates” shall mean any corporation or other entity which controls, is controlled by, or is under common control with AtriCure. A 
  
  

 Technology Transfer Agreement 
 Page 2 
  

 
corporation or other entity shall be regarded as in control of another corporation or entity if it owns or directly or indirectly controls more than fifty
percent (50%) of the voting stock or other ownership interest of the other corporation or entity, or if it possesses, directly or indirectly, the power to direct or cause the direction of the management and policies of the corporation or other
entity or the power to elect or appoint fifty percent (50 %) or more of the members of the governing body of the corporation or other entity. 
  
 1.2. “Arrhythmia Field of Use” shall mean the treatment of arrythmias that emanate in any chamber of the heart, or in any valve of the heart, or in any
major blood vessel that supports or delivers blood to or from the heart. 
  
 1.3.
“Cardiac Field of Use” shall mean the treatment of heart disease or disorders, excluding the Arrhythmia Field of Use. 
  
 1.4. “Core Patent Rights” shall mean the Enable Patent Rights and their foreign counterparts and all divisionals, continuations, continuations-in-part,
reissues, or reexaminations thereof throughout the world in existence before, on, or after the Effective Date. 
  
 1.5. “Core Intellectual Property Rights” shall mean the Hooven Technology and Related Materials, and all patents rights, know-how, processes, procedures, compositions, devices, methods, techniques,
data, sensors, software, improvements, or other subject matter disclosed in or derived therefrom, or other subject matter owned or controlled by Enable which arose in connection with the Enable Patent Rights and/or the Hooven Technology and/or the
Related Materials before the Effective Date. 
  
 1.6. “Other Technology
Rights” shall mean the Enable Technologies and all improvements in use or derived therefrom before the Effective Date. 
  
 Article 2. Transfer of Rights 
  
 2.1 Assignment. Enable hereby irrevocably sells and assigns to AtriCure, Enable’s entire right, title, and interest in the Core Patent Rights and the Core
Intellectual Property Rights in the Arrhythmia Field of Use, the Cardiac Field of Use, and all other fields of use, along with all claims, choate or inchoate, in all fields of use against any other invention, idea, or discovery arising during the
conduct of business by AtriCure after the Effective Date of this Agreement. 
  
 2.2. License Grant. Enable hereby grants to AtriCure an exclusive, worldwide, irrevocable, and royalty free right to use the Other Technology Rights to (i) design, develop, make, have made, use, sell, 

  

 Technology Transfer Agreement 
 Page 3 
  

 
or otherwise provide products in the Arrhythmia Field of Use, (ii) practice or authorize the practice of any method, process, or procedure in the Arrhythmia
Field of Use, and (iii) otherwise exploit the Core Patent Rights and Core Intellectual Property Rights in the Arrhythmia Field of Use. Enable also hereby grants to AtriCure a non-exclusive, worldwide, irrevocable, and royalty free right to use the
Other Technology Rights to (i) design, develop, make, have made, use, sell, or otherwise provide products in the Cardiac Field of Use, (ii) practice or authorize the practice of any method, process, or procedure in the Cardiac Field of Use, and
(iii) otherwise exploit the Core Patent Rights and Core Intellectual Property Rights in the Cardiac Field of Use. AtriCure shall have the unrestricted right to grant or authorize sublicenses within the scope of the licenses granted in this Section
2.2. To the extent that any aspect of the Other Technology Rights constitutes confidential and/or proprietary and/or trade secret information of Enable (the “Proprietary Enable Technology”), AtriCure will keep the Proprietary Enable
Technology confidential, unless and until Enable consents to its disclosure, or unless such information was otherwise previously known by AtriCure from a source other than Enable, or unless such information becomes generally available to the public
through no fault of AtriCure. Enable will cooperate with AtriCure in providing access to the Other Technology Rights, as requested by AtriCure in order to practice the Other Technology Rights pursuant to this Agreement. 
  
 2.3. Securing AtriCure’s Rights. Enable shall further secure AtriCure’s
rights in the Arrhythmia Field of Use by agreeing (i) to use its (Enable’s) best efforts in its regulatory approval process to avoid product uses or techniques in the Arrhythmia Field of Use; and (ii) to not itself engage in or aid another in
the development, marketing, selling, or promotion of any product or technique in the Arrhythmia Field of Use. In the event that, after the Effective Date, Enable transfers, or sells, or otherwise grants ownership, use or control of an Enable
Technology Asset to a third party (the “Purchasing Party”); for example, by licensure, or by assignment, or pursuant to a merger, consolidation, or sale of assets, or by sale or exchange of Enable stock, in a transaction that is not
inconsistent with the transfer and licensure of rights to AtriCure under this Agreement (the “Asset Transfer Transaction”), Enable shall (i) disclose to the Purchasing Party AtriCure’s rights in the Cardiac Field of Use and the
Arrhythmia Field of Use under the Enable Technologies pursuant to this Agreement, and (ii) continue to secure AtriCure’s rights in the Arrhythmia Field of Use by contractually obligating the Purchasing Party, its successors and assigns, as a
condition to the Asset Transfer Transaction and use of the Enable Technology Asset, to refrain from 

  

 Technology Transfer Agreement 
 Page 4 
  

 
using the Enable Technology Asset that is subject to the Asset Transfer Transaction, or technology that is derived therefrom after the Asset Transfer
Transaction, to engage or aid in the development, marketing, selling, or promotion of any product or technique in the Arrhythmia Field of Use. For the purposes of this provision, the term “Enable Technology Asset” shall mean any invention,
trade secret, copyright, data, regulatory submission and any other intellectual property of any kind developed by or otherwise owned or controlled by Enable at the time of the Asset Transfer Transaction, including, but not limited to, the Enable
Technologies set forth in Schedule D. 
  
 2.4. Improvements. Enable
acknowledges that AtriCure shall exclusively own all intellectual property rights and other technology rights in the Arrhythmia Field of Use, the Cardiac Field of Use, and all other fields of use that employees, agents, consultants, or contractors
of AtriCure conceive or develop after the Effective Date (the “AtriCure Improvements”). AtriCure shall have no obligation to provide Enable information about or access to the AtriCure Improvements. 
  
 Article 3. Consideration 
  
 3.1. Consideration. The issuance to Enable of 6,660,875 shares of common stock of
AtriCure on November 11, 2000 is the consideration for the undertakings and obligations of Enable under Article 2 of this Agreement. Additional consideration for the licenses granted by Enable to Atricure in the Cardiac Field of Use under ¶2.2
is the payment by AtriCure to Enable of the sum of $150,000, of which $90,000 has been paid by AtriCure prior to the Effective Date, leaving a balance due as of the Effective Date of $60,000, which will be paid by AtriCure to Enable in four (4)
monthly installments of $15,000 each, commencing on the Effective Date. 
  
 Article 4. The Service Agreement 
  
 4.1. Service
Agreement. Enable shall provide AtriCure design support and program management as requested by AtriCure under the Service Agreement, which is incorporated into the Agreement as Exhibit E, which Enable and AtriCure shall execute on even date
herewith. 
  
 Article 5. Representations and Warranties

  
 5.1. Enable’s Authorization. Enable represents and warrants
that: (i) it has the legal right, title, and power to enter into this Agreement and to extend the rights and/or licenses granted to AtriCure in this Agreement, (ii) the performance of such obligations will not conflict with Enable’s charter
documents or any agreements, contracts or other arrangements to which it is a party, (iii) Enable has not previously 

  

 Technology Transfer Agreement 
 Page 5 
  

 
granted and will not grant any rights in the Core Patent Rights, Core Intellectual Property Rights, or Other Technology Rights that are inconsistent with the
rights and licenses granted to AtriCure herein; (iv) that Enable is a corporation duly organized, validly existing and in good standing under the laws of the State of Delaware and has taken all necessary action to authorize the execution, delivery
and performance of this Agreement, and (v) upon the execution and delivery of this Agreement, this Agreement shall constitute a valid and binding obligation of Enable and its assigns and successors, enforceable in accordance with its terms.

  
 5.2. Further Representations by Enable. Enable represents and warrants
that, as of the Effective Date (i) Schedule A lists all Enable Patent Rights throughout the world; (ii) Enable owns or controls the Core Patent Rights, Core Intellectual Property Rights, and Other Technology Rights, and (iii) Enable has the right to
grant or convey the rights to AtriCure provided in this Agreement. To the best of Enable’s knowledge, (i) there is no pending or threatened claim or litigation contesting the ownership, derivation, inventorship, validity or right to use any of
the Core Patent Rights, Core Intellectual Property Rights, or Other Technology Rights, and (ii) Enable has not received any notice of infringement with respect to the Core Patent Rights, Core Intellectual Property Rights, or Other Technology Rights.

  
 Article 6. Miscellaneous 
  
 6.1. Assignment. This Agreement may be assigned or otherwise transferred by any party
without the consent of the other party. 
  
 6.2 Applicable Law. This
License Agreement shall be governed by and construed in accordance with the laws of the State of Ohio, without giving effect to the choice of laws provisions thereof. 
  
 6.3 Entire Agreement. This Agreement, together with the appendices hereto, contains the entire understanding of the parties with
respect to the subject matter hereof and supersedes all previous discussions and agreements between the parties, except the provisions of the assignments contained in Schedules A, B, and C, which are incorporated into this Agreement, and the
assignment of assets by Enable to AtriCure, dated November 1, 2000, which this Agreement clarifies and incorporates by reference. Otherwise, all express or implied agreements and understandings, either oral or written, heretofore made with respect
to the subject matter of this Agreement are expressly merged in and made a part of this Agreement. This Agreement may be amended, or any term hereof modified, only by a written instrument duly executed by both parties hereto. 
  

 Technology Transfer Agreement 
 Page 6 
  

 6.4. Savings Clause. Should any valid federal or state law or final determination of any administrative agency
or court of competent jurisdiction invalidate or otherwise affect any provision of this Agreement, the provision or provisions so affected shall be conformed automatically and to the extent possible to the law or determination in question, and in
all events the remaining provisions of this Agreement shall continue in full force and effect. 
  
 6.5 Counterparts. This Agreement maybe executed in two or more counterparts, each of which shall be deemed an original, but all of which together shall constitute one and the same instrument. 
  
 IN WITNESS WHEREOF, the parties have executed this Agreement as of the
Effective Date set forth above. 
  

									
	 Enable Medical Corporation
	 	 	 	 AtriCure, Incorporated

					
	By:	 	

	 	 	 	By:	 	

	 Name:
	 	 Michael D. Hooven
	 	 	 	 Name:
	 	 Michael D. Hooven

	 Title:
	 	 President
	 	 	 	 Title:
	 	 President

	 Date:
	 	 May 25, 2001
	 	 	 	 Date:
	 	 May 25, 2001

  

 Technology Transfer Agreement 
 Page 7 
  
 SCHEDULE A TO
AGREEMENT 
  
 LISTING OF ENABLE PATENT RIGHTS

  
 (WITH SUPPORTING ASSIGNMENTS) 
  
 1. United States Provisional Application Serial No. 60/200,072 entitled
“Method and Apparatus for Transmural Ablation,” filed April 27, 2000 (Attorney Docket Hoov 110). 
  
 2. United States Application Serial No. 09/747,609 entitled “Method and Apparatus for Transmural Ablation,” filed December 22, 2000 (Attorney
Docket Hoov 111A). 
  
 3. United States Application Serial No.
(not yet received) entitled “ Transmural Ablation Device and Method,” filed April 27, 2001, by Michael D. Hooven and James A. Chaldekas (Attorney Docket Hoov 111B). 
  
 4. Patent Cooperation Treaty (PCT) Application Serial No. PCT/US01/13766, entitled “ Transmural Ablation Device and
Method,” filed April 27, 2001, by Michael D. Hooven and James A. Chaldekas. 
  

			
	Serial No. 60/200,072	 	 
	 	 	Attorney Docket No.Hoov 110
	Filed April 27, 2000	 	 

  
 ASSIGNMENT TO ENABLE

  
 For good and valuable consideration, the receipt and
sufficiency of which is hereby acknowledged, Michael D. Hooven and James A. Chaldekas (hereinafter referred to as Assignors) assign to Enable Medical Corporation (hereinafter referred to as Assignee), a Delaware corporation, having a principal place
of business at 6345 Centre Park Drive. West Chester. Ohio 45069, its successors, legal representatives and assigns, the entire right, title and interest throughout the world, in Assignors’ invention or improvement in Method and Apparatus for
Transmural Ablation, as described in the Provision Application for Letters Patent of the United States, serial number 60/200,072, filed April 27, 2000, in such application and in any and all other applications in the United States or any other
countries, regular and provisional, which Assignors may file, either solely or jointly with others, on such invention or improvements, in all other applications in the United States or any other countries, regular and provisional, which Assignors
may file, either solely or jointly with others, claiming priority (under international convention, internal priority legislation, 35 USC 119(e), or other statute or treaty) from the above-identified application, and in any and all Letters Patent of
the United States or of any other country which may be obtained on any of the above applications, and, in any division, continuation, reexamination, reissue or extension of any of the foregoing. 
  
 Assignors warrant that they are the owners of the entire right, title and
interest in and to the invention and patent application herein assigned and have the right to make this assignment; and further warrant that they have conveyed to others no outstanding prior assignments, licenses, or other rights whatsoever in the
interest herein assigned. 
  
 Assignors hereby agree, upon the
request and at the expense of Assignee, its successors, legal representatives and assigns, to execute any and all regular, divisional, continuation, and renewal applications for such invention or improvements, and any necessary oath or supplemental
oath or affidavit relating thereto, and any application for the reissue or extension of any Letters Patent that may be granted upon such application that Assignee, its successors, legal representatives and assigns may deem necessary or expedient.

  
 Assignors further agree upon the request of Assignee, its
successors, legal representatives and assigns, in the event of such applications, or any regular application referring thereto, or any continuation or division thereof, or Letters Patent issued thereon, or any reissue or application for the reissue
thereof becoming involved in Interference or any other contested matter to cooperate to the best of their ability with Assignee, its successors, legal 

  

 1 

 
representatives and assigns in the matters of preparing and executing the preliminary statement or other such document and giving and producing evidence in
support thereof. Assignors further agree to perform, upon such request, any and all affirmative acts to obtain such Letters Patent, and vest all rights therein hereby conveyed in the Assignee, its successors, legal representatives and assigns
whereby such Letters Patent will be held and enjoyed by the Assignee, its successors, legal representatives and assigns to the end of the term for which such Letters Patent may be granted as fully and entirely as the same would have been held and
enjoyed by Assignors if this assignment and sale had not been made. 
  
 Assignors also assign to Assignee, its successors, legal representatives and assigns the right of priority for patent and utility model applications in all countries arising under any applicable international convention for the protection of industrial property and/or any internal priority legislation of such countries, and Assignors agree upon the
request of Assignee, its successors, legal representatives and assigns to execute any and all documents that shall be required to be executed in connection with any and all applications for foreign Letters Patent thereof, including the prosecution
thereof, and to execute any and all documents necessary to invest title in such foreign applications and patents in Assignee. 
  

			
		
	

	 	4/30/01
	 Michael D. Hooven
	 	Date

  
 County of Warren 
 State of Ohio 
  
 Signed before me this 30 day of April, 2001. 
  

	
	
	

	 Notary Public

  

			
		
	

	 	5/2/01
	 James A. Chaldekas
	 	Date

  
 County of Boulder 
 State of Colorado 
  
 Signed before me this 2nd day of May, 2001. 
  

	
	
	

	 Notary Public
 My Commission Expires 08/11/2001

  

 - 2 - 

			
	Serial No. 09/747,609	  	 
		
	 Filed December 22, 2000
	  	Attorney Docket No.Hoov 111A

  
 ASSIGNMENT TO
ENABLE 
  
 For good and valuable consideration, the
receipt and sufficiency of which is hereby acknowledged, Michael D. Hooven (hereinafter referred to as Assignor) assigns to Enable Medical Corporation (hereinafter referred to as Assignee), a Delaware corporation, having a principal place of
business at 6345 Centre Park Drive, West Chester, Ohio 45069, its successors, legal representatives and assigns, the entire right, title and interest throughout the world, in Assignor’s invention or improvement in Method for Transmural
Ablation, as described and claimed in the Application for Letters Patent of the United States, serial number 09/747,609, filed December 22, 2000, in such application and in any and all other applications in the United States or any other countries,
regular and provisional, which Assignor may file, either solely or jointly with others, on such invention or improvements, in all other applications in the United States or any other countries, regular and provisional, which Assignor may file,
either solely or jointly with others, claiming priority (under international convention, internal priority legislation, 35 USC 119(e), or other statute or treaty) from the above-identified application, and in any and all Letters Patent of the United
States or of any other country which may be obtained on any of the above applications, and, in any division, continuation, reexamination, reissue or extension of any of the foregoing. 
  
 Assignor warrants that he is the owner of the entire right, title and interest in and to the invention and patent
application herein assigned and has the right to make this assignment; and further warrant that he has conveyed to others no outstanding prior assignments, licenses, or other rights whatsoever in the interest herein assigned. 
  
 Assignor hereby agrees, upon the request and at the expense of Assignee, its
successors, legal representatives and assigns, to execute any and all regular, divisional, continuation, and renewal applications for such invention or improvements, and any necessary oath or supplemental oath or affidavit relating thereto, and any
application for the reissue or extension of any Letters Patent that may be granted upon such application that Assignee, its successors, legal representatives and assigns may deem necessary or expedient. 
  
 Assignor further agrees upon the request of Assignee, its successors, legal
representatives and assigns, in the event of such applications, or any regular application referring thereto, 

  

 1 

 
or any continuation or division thereof, or Letters Patent issued thereon, or any reissue or application for the reissue thereof becoming involved in
Interference or any other contested matter to cooperate to the best of his ability with Assignee, its successors, legal representatives and assigns in the matters of preparing and executing the preliminary statement or other such document and giving
and producing evidence in support thereof. Assignor further agrees to perform, upon such request, any and all affirmative acts to obtain such Letters Patent, and vest all rights therein hereby conveyed in the Assignee, its successors, legal
representatives and assigns whereby such Letters Patent will be held and enjoyed by the Assignee, its successors, legal representatives and assigns to the end of the term for which such Letters Patent may be granted as fully and entirely as the same
would have been held and enjoyed by Assignor if this assignment and sale had not been made. 
  
 Assignor also assigns to Assignee, its successors, legal representatives and
assigns the right of priority for patent and utility model applications in all countries arising under any applicable international convention for the protection of industrial property and/or any internal priority legislation of such countries, and
Assignor agrees upon the request of Assignee, its successors, legal representatives and assigns to execute any and all documents that shall be required to be executed in connection with any and all applications for foreign Letters Patent thereof,
including the prosecution thereof, and to execute any and all documents necessary to invest title in such foreign applications and patents in Assignee. 
  

					
			
	

	 	 	 	  
	 Michael D. Hooven
	 	 	 	 Date: 4/30/01

			
	 County of Warren
	 	 	 	 
	 State of Ohio
	 	 	 	 
			
	 Signed before me this 30 day of April, 2001.
	 	 	 	 
			
	 

	 	 	 	 
	 Notary Public
	 	 	 	 

  

 2 

			
	Serial No.                     	  	 Attorney Docket No.Hoov 111B

	 Filed April 27, 2001
	  

  
 ASSIGNMENT TO
ENABLE 
  
 For good and valuable consideration, the
receipt and sufficiency of which is hereby acknowledged, Michael D. Hooven and James A. Chaldekas (hereinafter referred to as Assignors) assign to Enable Medical Corporation (hereinafter referred to as Assignee), a Delaware corporation, having a
principal place of business at 6345 Centre Park Drive, West Chester, Ohio 45069, its successors, legal representatives and assigns, the entire right, title and interest throughout the world, in Assignors’ invention or, improvement in Transmural
Ablation Device and Method, as described in the Application for Letters Patent of the United States, serial number (not vet assigned), filed April 27, 2001, in such application and in any and all other applications in the United States or any other
countries, regular and provisional, which Assignors may file, either solely or jointly with others, on such invention or improvements, in all other applications in the United States or any other countries, regular and provisional, which Assignors
may file, either solely or jointly with others, claiming priority (under international convention, internal priority legislation, 35 USC 119(e), or other statute or treaty) from the above-identified application, and in any and all Letters Patent of
the United States or of any other country which may be obtained on any of the above applications, and, in any division, continuation, reexamination, reissue or extension of any of the foregoing. 
  
 Assignors warrant that they are the owners of the entire right, title and
interest in and to the invention and patent application herein assigned and have the right to make this assignment; and further warrant that they have conveyed to others no outstanding prior assignments, licenses, or other rights whatsoever in the
interest herein assigned. 
  
 Assignors hereby agree, upon the
request and at the expense of Assignee, its successors, legal representatives and assigns, to execute any and all regular, divisional, continuation, and renewal applications for such invention or improvements, and any necessary oath or supplemental
oath or affidavit relating thereto, and any application for the reissue or extension of any Letters Patent that may be granted upon such application that Assignee, its successors, legal representatives and assigns may deem necessary or expedient.

  
 Assignors further agree upon the request of Assignee, its
successors, legal representatives and assigns, in the event of such applications, or any regular application referring thereto, or any continuation or division thereof, or Letters Patent issued thereon, or any reissue or application for the reissue
thereof becoming involved in Interference or any other contested matter to cooperate to the best of their ability with Assignee, its successors, legal representatives and assigns in the matters of preparing and 

  

 1 

 
executing the preliminary statement or other such document and giving and producing evidence in support thereof. Assignors further agree to perform, upon
such request, any and all affirmative acts to obtain such Letters Patent, and vest all rights therein hereby conveyed in the Assignee, its successors, legal representatives and assigns whereby such Letters Patent will be held and enjoyed by the
Assignee, its successors, legal representatives and assigns to the end of the term for which such Letters Patent may be granted as fully and entirely as the same would have been held and enjoyed by Assignors if this assignment and sale had not been
made. 
  
 Assignors also assign to Assignee, its successors, legal
representatives and assign the right of priority for patent and utility model applications in all countries arising under any applicable international convention, for the protection of industrial property and/or any internal priority legislation of
such countries, and Assignors agree upon the request of Assignee, its successors, legal representatives and assigns to execute any and all documents that shall be required to be executed in connection with any and all applications for foreign
Letters Patent thereof, including the prosecution thereof, and to execute any and all documents necessary to invest title in such foreign applications and patents in Assignee. 
  

					
			
	

	 	 	 	 4/30/01

	 Michael D. Hooven
	 	 	 	 Date

  
 County of Warren 
 State of Ohio 
  
 Signed before me this 30 day of April, 2001. 
  

	
	
	

	 Notary Public

  

					
			
	

	 	 	 	 5/2/01

	 James A. Chaldekas
	 	 	 	 Date

  
 County of Boulder 
 State of Colorado 
  
 Signed before me this 2nd day of May, 2001. 
  

	
	
	

	 Notary Public
 My Commission Expires 08/11/2001

  

 - 2 - 

 All Applications 
  
 ASSIGNMENT FROM ENABLE TO ATRICURE 
  
 For good and valuable consideration, the receipt and sufficiency of which is hereby acknowledged, Enable Medical
Corporation, a Delaware Corporation with offices at 6345 Centre Park Drive, West Chester, Ohio 45069 (hereinafter referred to as Assignor), assigns to Atricure Inc., a Delaware Corporation with offices at 6033 Schumacher Park Drive, West Chester,
Ohio 45069 (hereinafter referred to as Assignee), its successors, legal representatives and assigns, the entire right, title and interest throughout the world, which Assignor now has or later acquires, in the invention or improvement in each of the
United States Patent Applications set forth in the attached Exhibit A, in such applications and any and all other applications in the United States or any other countries, regular and provisional, which may be filed, either solely or jointly with
others, on such invention or improvements, in all other applications in the United States or any other countries, regular and provisional, which may be filed, either solely or jointly with others, claiming priority (under international convention,
internal priority legislation, 35 USC 119 (e), or other statute or treaty) from the above-identified application, and in any and all Letters Patents of the United States or of any other country which may be obtained on any of the above applications,
and, in any division, continuation, reexamination, reissue or extension of any of the foregoing. 
  
 Assignor warrants that it is the owner of the entire right, title and interest in and to the inventions and patent applications herein assigned and has
the right to make this assignment; and further warrants that it has conveyed to others no outstanding prior assignments, licenses, or other rights whatsoever in the interest herein assigned. 
  
 Assignor hereby agrees, upon the request of Assignee, its successors, legal
representatives and assigns, to execute or cause the proper execution of any and all regular, divisional, continuation, and renewal applications for such inventions or improvements, and any necessary oath or supplemental oath or affidavit relating
thereto, and any application for the reissue or extension of any Letters Patent that may be granted upon such application that Assignee, its successors, legal representatives and assigns may deem necessary or expedient. 
  
 Assignor further agrees upon the request of Assignee, its successors, legal
representatives and assigns, in the event of such applications, or any regular application referring thereto, or any continuation or division thereof, or Letters Patent issued thereon, or any reissue or application for the reissue thereof becoming
involved in Interference or any other contested matter to cooperate with Assignee, its successors, legal representatives and assigns in the matters of preparing and executing the 

  

 
preliminary statement or other such document and giving and producing evidence in support thereof. Assignor further agrees to perform, upon such request, any
and all affirmative acts to obtain such Letters Patent, and vest all rights therein hereby conveyed in the Assignee, its successors, legal representatives and assigns whereby such Letters Patent will be held and enjoyed by the Assignee, its
successors, legal representatives and assigns to the end of the term for which such Letters Patent may be granted as fully and entirely as the same would have been held and enjoyed by Assignor if this assignment and sale had not been made.

  
 Assignor also, with respect to each of the applications listed
in Exhibit A, assigns to Assignee, its successors, legal representatives and assigns the right of priority for patent and utility model applications in all countries arising under any applicable international convention for the protection of
industrial property and/or any internal priority legislation of such countries, and Assignor agrees upon the request of Assignee, its successors, legal representatives and assigns to execute or cause the proper execution of any and all documents
that shall be required to be executed in connection with any and all applications for foreign Letters Patent, including the prosecution thereof, and to execute any and all documents necessary to invest title in such foreign applications and patents
in Assignee. 
  

									
	 Enable Medical Corporation
	 	 	 	 	 	 
					
	 by:
	 	

	 	 	 	 Date:
	 	 5/3/01

	 title:
	 	 President
	 	 	 	 	 	 

  
 County of Butler 
 State of Ohio 
  
 Signed before me this 3rd day of May, 2001. 
  

	
	
	

	 Notary Public

	 Kimberly K. Meece
 Notary Public, State of Ohio
 My Commission Expires Nov. 27, 2004

  

 Exhibit A to the Assignment from Enable to Atricure 
  
 1. Unites States Provisional Application Serial No. 60/200,072 entitled “Method and
Apparatus for Transmural Ablation” and filed April 27, 2000. 
  
 2. United
States Patent Application Serial No. 09/747,609 entitled “Method for Transmural Ablation” and filed December 22, 2000. 
  
 3. United States Patent Application Serial No. (not yet assigned). entitled “Transmural Ablation Device and Method”, filed April 27, 2001, by
Michael D. Hooven and James A. Chaldekas. 
  
 4. Patent Cooperation Treaty
Application Serial No. (not yet assigned). entitled “Transmural Ablation Device and Method”, filed April 27, 2001, by Michael D. Hooven and James A. Chaldekas. 
  

 3 

 Technology Transfer Agreement 
 Page 8 
  
 SCHEDULE B TO
AGREEMENT 
  
 LISTING OF HOOVEN TECHNOLOGY 

 
 (WITH SUPPORTING ASSIGNMENTS) 
  
 Hooven Notebook Pages 32 to 33; 51; 57 to 61; 63 to 75; and 78 to 103

  

 Notebook Pages 
  
 ASSIGNMENT TO ENABLE 
  

For good and valuable consideration, the receipt and sufficiency of which is hereby acknowledged, Michael D. Hooven (hereinafter referred to as
Assignor) assigns to Enable Medical Corporation (hereinafter referred to as Assignee), a Delaware corporation, having a principal place of business at 6345 Centre Park Drive. West Chester, Ohio 45069. its successors, legal representatives and
assigns, the entire right, title and interest throughout the world, in any and all ideas, concepts, inventions or improvements (“Subject Matter”) disclosed in the attached laboratory notebook pages, in any patent application in the United
States or any other countries, regular and provisional, which Assignor may file, either solely or jointly with others, on such Subject Matter, in all other applications in the United States or any other countries, regular and provisional, which
Assignor may file, either solely or jointly with others, claiming priority (under international convention, internal priority legislation, 35 USC 119(e), or other statute or treaty) from any of such applications, and in any and all Letters Patent of
the United States or of any other country which may be obtained on any of the above applications, and, in any division, continuation, reexamination, reissue or extension of any of the foregoing. 
  
 Assignor warrants that he is the owner of the entire right, title and
interest in and to the Subject Matter and has the right to make this assignment; and further warrants that he has conveyed to others no outstanding prior assignments, licenses, or other rights whatsoever in the interest herein assigned. 

 
 Assignor hereby agrees, upon the request and at the expense of Assignee,
its successors, legal representatives and assigns, to execute any and all regular, divisional, continuation, and renewal applications for such invention or improvements, and any necessary oath or supplemental oath or affidavit relating thereto, and
any application for the reissue or extension of any Letters Patent that may be granted for such inventions that Assignee, its successors, legal representatives and assigns may deem necessary or expedient. 
  
 Assignor further agrees upon the request of Assignee, its successors, legal
representatives and assigns, in the event of such applications, or any regular application referring thereto, or any continuation or division thereof, or Letters Patent issued thereon, or any reissue or application for the reissue thereof becoming
involved in Interference or any other contested matter to cooperate to the best of his ability with Assignee, its successors, legal representatives and assigns in the matters of preparing and executing the preliminary statement or other such
document and giving and producing evidence in support thereof. 

  

 
Assignor further agrees to perform, upon such request, any and all affirmative acts to obtain such Letters Patent, and vest all rights therein hereby
conveyed in the Assignee, its successors, legal representatives and assigns whereby such Letters Patent will be held and enjoyed by the Assignee, its successors, legal representatives and assigns to the end of the term for which such Letters Patent
may be granted as fully and entirely as the same would have been held and enjoyed by Assignor if this assignment and sale had not been made. 
  
 Assignor also, with respect to any inventions disclosed in the attached notebook pages, assigns to Assignee, its successors, legal representatives and
assigns the right of priority for patent and utility model applications in all countries arising under any applicable international convention for the protection of industrial property and/or any internal priority legislation of such countries, and
Assignor agrees upon the request of Assignee, its successors, legal representatives and assigns to execute any and all documents that shall be required to be executed in connection with any and all applications for foreign Letters Patent thereof,
including the prosecution thereof, and to execute any and all documents necessary to invest title in such foreign applications and patents in Assignee. 
  

					
			
	

	 	 	 	 Date: 4/30/01

	 Michael D. Hooven
	 	 	 	 

  
 County of Warren 
 State of Ohio 
  
 Signed before me this 30 day of April, 2001. 
  

	
	
	

	 Notary Public
 Amanda S. Lutes
 Notary Public
 by and for the State of Ohio
 My Commission Expires
 November 11, 2002

  

 2 

 [VARIOUS DIAGRAMS OF TRANSMURAL ABLATION DEVICE] 
  

 Notebook Pages 
  
 ASSIGNMENT FROM ENABLE TO ATRICURE 
  
 For good and valuable consideration, the receipt and sufficiency of which is hereby acknowledged, Enable Medical
Corporation, a Delaware Corporation with offices at 6345 Centre Park Drive, West Chester, Ohio 45069 (hereinafter referred to as Assignor), assigns to Atricure Inc., a Delaware Corporation with offices at 6033 Schumacher Park Drive, West Chester,
Ohio 45069 (hereinafter referred to as Assignee), its successors, legal representatives and assigns, the entire right, title and interest throughout the world, which Assignor now has or later acquires, in any and all ideas, concepts, inventions or
improvements (“Subject Matter”) disclosed in the attached laboratory notebook pages, in any patent application in the United States or any other countries, regular and provisional, which may be filed, either solely or jointly with others,
on such Subject Matter, in all other applications in the United States or any other countries, regular and provisional, which may be filed, either solely or jointly with others, claiming priority (under international convention, internal priority
legislation, 35 USC 119 (e), or other statute or treaty) from any of such applications, and in any and all Letters Patent of the United States or of any other country which may be obtained on any of the above applications, and, in any division,
continuation, reexamination, reissue or extension of any of the foregoing. 
  
 Assignor warrants that it is the owner, through assignment, of the entire right, title and interest in and to the invention(s) and has the right to make this assignment; and further warrants that it has conveyed to
others no outstanding prior assignments, licenses, or other rights whatsoever in the interest herein assigned. 
  
 Assignor hereby agrees, upon the request and at the expense of Assignee, its successors, legal representatives and assigns, to execute or cause the proper
execution of any and all regular, divisional, continuation, and renewal applications for such invention or improvements, and any necessary oath or supplemental oath or affidavit relating thereto, and any application for the reissue or extension of
any Letters Patent that may be granted for such inventions that Assignee, its successors, legal representatives and assigns may deem necessary or expedient. 
  
 Assignor further agrees upon the request of Assignee, its successors, legal representatives and assigns, in the event of such applications, or any regular
application referring thereto, or any continuation or division thereof, or Letters Patent issued thereon, or any reissue or application for the reissue thereof becoming involved in Interference or any other contested matter to cooperate with
Assignee, its successors, legal representatives and assigns in the matters of preparing and executing the preliminary statement or other such document and 

  

 
giving and producing evidence in support thereof. Assignor further agrees to perform, upon such request, any and all affirmative acts to obtain such Letters
Patent, and vest all rights therein hereby conveyed in the Assignee, its successors, legal representatives and assigns whereby such Letters Patent will be held and enjoyed by the Assignee, its successors, legal representatives and assigns to the end
of the term for which such Letters Patent may be granted as fully and entirely as the same would have been held and enjoyed by Assignor if this assignment and sale had not been made. 
  
 Assignor also, with respect to any inventions disclosed in the attached notebook pages, assigns to Assignee, its successors,
legal representatives and assigns the right of priority for patent and utility model applications in all countries arising under any applicable international convention for the protection of industrial property and/or any internal priority
legislation of such countries, and Assignor agrees upon the request of Assignee, its successors, legal representatives and assigns to execute or cause the proper execution of any and all documents that shall be required to be executed in connection
with any and all applications for foreign Letters Patent thereof, including the prosecution thereof, and to execute any and all documents necessary to invest title in such foreign applications and patents in Assignee. 
  

									
	 Enable Medical Corporation
	 	 	 	 
				
	by:	 	

	 	 	 	Date: 5/3/01
	 title:
	 	 President
	 	 	 	 	 	 

  
 County of Butler 
 State of Ohio 
  
 Signed before me this 3rd day of May, 2001. 
  

	
	
	

	 Notary Public
 Kimberly K. Meece
 Notary Public, State of Ohio
 My Commission Expires Nov. 27,
2004

  

 2 

  
 [VARIOUS DIAGRAMS OF
TRANSMURAL ABLATION DEVICE] 
  

 Technology Transfer Agreement 
 Page 9 
  
 SCHEDULE C TO
AGREEMENT 
  
 LISTING OF RELATED MATERIALS 

 
 (WITH SUPPORTING ASSIGNMENTS) 
  
 1. All Grace related patent files located in file cabinet #121. 

 
 2. All Quality files located in file cabinet #121. 
  
 3. Jane Gabbard’s Enable Book pages 1 to 3. 
  
 4. Jane Gabbard’s Lab Book pages 1 to 18. 
  
 5. Jane Gabbard’s Daily Log Books 1 and 2 from 5/1/2000 forward.

  
 6. Pat Alexander’s Enable Book page 1. 
  
 7. Pat Alexander’s Lab Book pages 1 to 15. 
  
 8. Pat Alexander’s Chart’s folder - charts dates to correspond with
lab note book and dates. 
  
 9. Pat Alexander’s Bench folder
- Bench top information for prototypes P1 to P7 from 4/1/2000 forward. 
  
 10. All information on laptop computer dated 5/1/2000 forward. 
  
 11. All information on the network under (attached printed files) 
  
 bugs/users/janeg 
  
 bugs/departments/Atricure 
  
 bugs/quality-regulatory/Atricure 
  
 bugs/users/pata
(contains bench top data and all lab data from 4/1/2000 forward) 
  
 12. Rick Nuchols’ Enable Book pages 4 to 6. 
  
 13.
Rick Nuchols’ folder containing dated drawings, notes from meetings, and photocopies of clamps. 
  
 14. Rick Nuchols’ directories c:\users\Rickn\pro-files\grace (printout attached) 
  
 15. Ken Miller’s Grace Prototypes. 
  

 Schedule C Assign 
  
 ASSIGNMENT TO ENABLE 
  

For good and valuable consideration, the receipt and sufficiency of which is hereby acknowledged, the undersigned individuals (hereinafter referred to
as Assignors) assign to Enable Medical Corporation (hereinafter referred to as Assignee), a Delaware corporation, having a principal place of business at 6345 Centre Park Drive, West Chester, Ohio 45069, its successors, legal representatives and
assigns, the entire right, title and interest throughout the world, in any and all ideas, concepts, inventions or improvements (“Subject Matter”) disclosed in the respective drawings, directories, prototypes, or Lab Book, Enable Books, or
Log Book pages listed in the attached “Schedule C to Agreement,” in any patent application in the United States or any other countries, regular and provisional, which any Assignor may file, either solely or jointly with others, on such
Subject Matter, in all other applications in the United States or any other countries, regular and provisional, which any Assignor may file, either solely or jointly with others, claiming priority (under international convention, internal priority
legislation, 35 USC 119 (e), or other statute or treaty) from any of such applications, and in any and all Letters Patent of the United States or of any other country which may be obtained on any of the above applications, and, in any division,
continuation, reexamination, reissue or extension of any of the foregoing. 
  
 Each Assignor warrants that he/she is the owner of the entire right, title and interest in and to the Subject Matter and has the right to make this assignment; and further warrants that he/she has conveyed to others
no outstanding prior assignments, licenses, or other rights whatsoever in the interest herein assigned. 
  
 Each Assignor hereby agrees, upon the request and at the expense of Assignee, its successors, legal representatives and assigns, to execute any and all
regular, divisional, continuation, and renewal applications for such invention or improvements, and any necessary oath or supplemental oath or affidavit relating thereto, and any application for the reissue or extension of any Letters Patent that
may be granted for such inventions that Assignee, its successors, legal representatives and assigns may deem necessary or expedient. 
  
 Each Assignor further agrees upon the request of Assignee, its successors, legal representatives and assigns, in the event of such applications, or any
regular application referring thereto, or any continuation or division thereof, or Letters Patent issued thereon, or any reissue or application for the reissue thereof becoming involved in Interference or any other 

  

 Page 1 of 3 

 
contested matter to cooperate to the best of his/her ability with Assignee, its successors, legal representatives and assigns in the matters of preparing and
executing the preliminary statement or other such document and giving and producing evidence in support thereof. Each Assignor further agrees to perform, upon such request, any and all affirmative acts to obtain such Letters Patent, and vest all
rights therein hereby conveyed in the Assignee, its successors, legal representatives and assigns whereby such Letters Patent will be held and enjoyed by the Assignee, its successors, legal representatives and assigns to the end of the term for
which such Letters Patent may be granted as fully and entirely as the same would have been held and enjoyed by Assignor if this assignment and sale had not been made. 
  
 Each Assignor also, with respect to any inventions assigned herein also assigns to Assignee, its successors, legal
representatives and assigns the right of priority for patent and utility model applications in all countries arising under any applicable international convention for the protection of industrial property and/or any internal priority legislation of
such countries, and each Assignor agrees upon the request of Assignee, its successors, legal representatives and assigns to execute any and all documents that shall be required to be executed in connection with any and all applications for foreign
Letters Patent thereof, including the prosecution thereof, and to execute any and all documents necessary to invest title in such foreign applications and patents in Assignee. 
  

					
			
	

	 	 	 	 
	 Jane Gabbard
	 	 Date:
	 	 5/17/01

  
 County of Butler 
 State of Ohio 
  
 Signed before me this 17th day of May, 2001. 
  

	
	
	

	 Notary Public
 Christina R. Johnson
 Notary Public State of Ohio
 My Commission Expires Oct. 29,
2002

  

					
			
	

	 	 	 	 
	 Patrick Alexander
	 	 Date:
	 	 5/17/01

  
 County of Butler 
 State of Ohio 
  
 Signed before me this 17th day of May, 2001. 
  

	
	
	

	 Christina R. Johnson
 Notary Public State of Ohio
 My Commission Expires Oct. 29, 2002

  

 Page 2 of 3 

					
			
	

	 	 	 	  
	 Richard Nuchols
	 	 Date:
	 	 5/15/2001

			
	County of Clermont	 	 	 	 
	State of Ohio	 	 	 	 
			
	Signed before me this 15th day of May, 2001.	 	 	 	 Kimberly K. Meece

	 	 	 	 	 Notary Public, State of Ohio
 My Commission Expires Nov. 27, 2004

  
  

					
			
	

	 	  	 	  
	 Notary Public
	 	 	 	 

  

					
			
	

	 	 	 	  
	 Kenneth Miller
	 	 Date:
	 	 5/15/01

			
	 County of Butler
 State of Ohio
	 	 	 	 

  
  
 Signed before me this 15th day of May, 2001. 
  

					
			
	

	 	 	 	 Kimberly K. Meece

	 Notary Public
	 	 	 	 Notary Public, State of Ohio
 My Commission Expires Nov. 27, 2004

  

 Page 3 of 3 

 SCHEDULE C TO AGREEMENT 
  
 LISTING OF RELATED MATERIALS 
  

(WITH RELATED ASSIGNMENTS) 
  
 1. All Grace related patent files located in file cabinet #121. 
  

2. All Quality files located in file cabinet #121. 
  
 3. Jane Gabbard’s Enable Book pages 1 to 3. 
  
 4. Jane Gabbard’s Lab Book pages 1 to 18. 
  
 5. Jane Gabbard’s Daily Log Books 1 and 2 from 5/1/2000 forward. 
  
 6 Pat Alexander’s Enable Book page 1. 
  
 7. Pat Alexander’s Lab Book pages 1 to 15. 
  
 8. Pat Alexander’s Chart’s folder - charts dates to correspond with lab note book and dates. 
  
 9. Pat Alexander’s Bench folder - Bench top information for prototypes
P1 to P7 from 4/1/2000 forward. 
  
 10. All information on laptop
computer dated 5/1/2000 forward. 
  
 11. All information on the
network under (attached printed files) 
  
 bugs/users/janeg

  
 bugs/departments/Atricure 
  
 bugs/quality-regulatory/Atricure 
  
 bugs/users/pata (contains bench top data and all lab data from 4/1/2000
forward) 
  
 12. Rick Nuchol’s Enable Book pages 4 to 6.

  
 13. Rick Nuchol’s folder containing dated drawings, notes
from meetings, and photocopies of clamps. 
  
 14. Rick
Nuchol’s directories c:\users\Rickn\pro-files\grace (printout attached) 
  
 15. Ken Miller’s Grace Prototypes. 
  

 Technology Transfer Agreement 
 Page 10 
  
 SCHEDULE D TO
AGREEMENT 
  
 LISTING OF ENABLE TECHNOLOGIES 

 
 1. Electrostatic Nylon Coating Systems, Processes, and Techniques.

  
 2. Electroless Plating Systems, Processes, and Techniques.

  
 3. Electrolytic Plating Systems, Processes, and Techniques.

  
 4. Pickling or Passivating Systems, Processes, and Techniques.

  
 5. Any Related Surface Preparation or Material Deposition
Systems, Processes, and Techniques. 
  
 6. Thermal Forming/Curving
Systems, Processes, and Techniques. 
  
 7. Resistive Ink Pad
Printing Systems, Processes, and Techniques. 

 Technology Transfer Agreement 
 Page 11 
  

 SCHEDULE E TO AGREEMENT 
  
 SERVICE AGREEMENT BETWEEN ENABLE AND ATRICURE 
  
 This Service Agreement (the “Service Agreement”) is effective May 25, 2001 (the “Effective Date”) and is
between Enable Medical Corporation, a Delaware Corporation having offices at 6345 Centre Park Drive, West Chester, Ohio 45069 (“Enable”) and AtriCure, Inc., a Delaware Corporation having offices at 6033 Schumacher Park Drive, West Chester,
Ohio 45069 (“AtriCure”). 
  
 This Service Agreement is incorporated by
reference into the Technology Transfer Agreement between Enable and AtriCure of even date. 
  
 1. Scope of Work. Enable shall provide AtriCure design support and program management as requested by AtriCure, as set forth in the attached Project Plan, entitled Grace Plan Worksheet (Enable Support) (the
“Contract Services”). 
  
 2. Compensation. AtriCure shall pay
Enable for the Contract Services received according to the attached Budget, entitled Enable Budget for PMBS Hand-Piece Development. Enable shall invoice AtriCure at the beginning of each month for the Contract Services provided. Milestone activities
shall be invoiced upon receipt of purchase order and upon completion of milestone. Terms of the invoice shall be net 15 days. AtriCure shall retain the right to review evidence of service hours provided. 
  
 3. Deliverables. A mutually agreed upon list of milestones, delivery dates and
payments related to the Contract Services is included in the attached Project Plan and Budget (the “Deliverables”). The Deliverables shall be completed and delivered to AtriCure on or before the specified date. The Deliverables schedules
may be reviewed and revised as required on a quarterly basis. Separate purchase orders shall be provided by for each Deliverable. The terms of such purchase order shall be 50% upon receipt of order, 50% upon delivery of the Deliverable. 

 
 4. Manner of Performance. Enable represents that Enable has the requisite
expertise, ability and legal right to render the Contract Services, and will perform the Contract Services in an efficient manner and in accordance with the terms of this Service Agreement. Enable will abide by all laws, rules and regulations that
apply to the performance of the Contract Services. Enable is an independent contractor, and shall not be considered an employee of AtriCure. AtriCure will not be responsible for Enable’s acts 

  

 Technology Transfer Agreement 
 Page 12 
  

 
while performing the Contract Services, whether on AtriCure’s premises or elsewhere, and Enable will not have authority to speak for, represent, or
obligate AtriCure in any way. 
  
 5. Confidentiality. During discussions
leading up to this Service Agreement, and during the course of the Contract Services performed pursuant to this Service Agreement, it is anticipated that Enable will learn confidential and/or proprietary information of AtriCure. Enable will keep
confidential, and not use, except in connection with the Contract Services to be provided hereunder, information which is provided to Enable by AtriCure and/or developed by Enable while performing Contract Services, including without limitation,
information concerning AtriCure’s products, manufacturing processes, customers, product pricing, and technical know-how, unless and until AtriCure consents to disclosure, or unless such information otherwise was previously known by Enable, as
documented by Enable in writing, or becomes generally available to the public through no fault of Enable. 
  
 Enable further represents that any and all information disclosed to AtriCure, or used for the benefit of AtriCure by Enable does not include any
confidential, trade secret or proprietary information of others. 
  
 Enable will not disclose to others, without AtriCure’s consent, the fact that it is acting on behalf of AtriCure. Upon AtriCure’s request, after the termination of this Service Agreement, Enable will use its best efforts to return
to AtriCure all copies of drawings, specifications, manuals and other printed or reproduced material (including information stored on machine readable media) provided to Enable by AtriCure or developed by Enable during the performance of Contract
Services under this Service Agreement. 
  
 Enable acknowledges
that in order to provide the Contract Services under this Service Agreement it may be necessary to utilize AtriCure’s confidential information at its premises. Enable thus agrees that, in order to maintain the confidentiality of AtriCure’s
confidential information and the confidentiality of its Contract Services, it will segregate the Contract Services performed at its premises from other work. Such segregation will insure that AtriCure’s confidential information will not be
visible to visitors to Enable’s facilities. 
  
 The
obligations of non-use and confidentiality of such information shall survive the termination of this Service Agreement. 
  

 Technology Transfer Agreement 
 Page 13 
  

 6. Conflicts of Interest. Enable represents that it has advised AtriCure in writing prior to the date of
signing this Service Agreement of any relationship with third parties, including competitors of AtriCure, which would present a conflict of interest with the Contract Services, or which would prevent Enable from carrying out the terms of this
Service Agreement. Enable agrees to advise AtriCure of any such relationships that arise during the term of this Service Agreement. 
  
 Upon learning of the occurrence of any of the described conflicts, AtriCure may terminate this Service Agreement without further liability to Enable,
except to pay for any Contract Services actually rendered. Enable shall have no recourse against AtriCure for termination under this Article. 
  
 7. Ownership of Developments. Enable agrees and does hereby assign to AtriCure in all fields of use, any and all of Enable’s interest in any inventions or
discoveries, which includes all written materials and other works which may be subject to copyright, and all patentable and unpatentable inventions, discoveries, and ideas (including but not limited to any computer software) which are reduced to
practice, conceived or written by Enable during the term of this Service Agreement, and for ninety (90) days after it expires, and which are based upon any information received from AtriCure, and/or developed as a result of performing the Contract
Services for AtriCure (hereinafter “Development”). Enable agrees to hold all such Developments confidential in accordance with Article 5 of this Service Agreement. 
  
 Enable shall disclose promptly to AtriCure each such Development and, upon AtriCure’s request and at AtriCure’s
expense, Enable will assist AtriCure, or anyone it designates, in filing and prosecuting patent or copyright applications in any country in the world. Each copyrightable work, to the extent permitted by law, will be considered a work made for hire
and the authorship and copyright of the work shall be in AtriCure’s name. Enable will execute all papers and do all things which may be necessary or advisable, in the opinion of AtriCure, to prepare, file and prosecute such applications, and to
evidence the assignment in AtriCure, or its designee, of all right, title and interest in and to such Development. 
  
 8. Term. This Service Agreement shall remain in effect until Enable’s delivery, to AtriCure’s satisfaction, of the Contract Services. The Service
Agreement may be terminated by AtriCure without cause with sixty (60) days advance written notice to Enable. Enable and AtriCure shall review this Service Agreement quarterly in order to re-evaluate the payments and services to be provided in the
next 

  

 Technology Transfer Agreement 
 Page 14 
  

 
successive quarter (i.e. review in March the second quarter rates and services) and make any necessary adjustments to monthly billings. 
  
 9. General. No assignment by Enable of this Service Agreement, or any sums due under
it, will be binding on AtriCure without AtriCure’s prior written consent. This Service Agreement supersedes all prior agreements and understandings between the parties respecting the subject matter of this Service Agreement. This Service
Agreement may not be changed or terminated orally by or on behalf of either party. In the event either party breaches this Service Agreement, the other party will have the right to terminate the Service Agreement. In the event of the actual or
threatened breach, AtriCure will have the right to specific performance and injunctive relief. All rights that are established by Article 7 of this Service Agreement and that are in existence at the time of termination shall remain in effect after
termination. The rights granted by this Paragraph are in addition to all other remedies and rights available at law or in equity. This Service Agreement shall be construed according to the laws of Ohio for contracts made within the state.

  
 IN WITNESS WHEREOF, the parties have executed this Service
Agreement as of the Effective Date set forth above. 
  

									
	 Enable Medical Corporation
	 	 	 	 AtriCure, Incorporated

					
	By:	 	

	 	 	 	By:	 	

	 Name:
	 	 Michael D. Hooven
	 	 	 	 Name:
	 	 Michael D. Hooven

	 Title:
	 	 President
	 	 	 	 Title:
	 	 President

	 Date:
	 	 May 25, 2001
	 	 	 	 Date:
	 	 May 25, 2001

  

 Technology Transfer Agreement 
 Page 15 
  

 The Service Agreement 
  
 Project Plan 
  

 Grace Plan Worksheet 
 Enable Support 
  
 Concept/Feasibility Phase 
 (Estimated Task Duration: Through 5/10/01) 

																											
	 	 	 	 	 	 	 	  	 	  	 	  	/Hr

	 	 	 	  	 	 
	 Deliverable

	  	LT/Date

	  	Mat’l Cost

	 	 	Labor

	 	 	 Comments

	  	Who

	  	Init*

	  	Rate

	 	 	Pwks

	  	Total

	 
	 Build Bench top Test Electrodes
	  	2 weeks	  	$	[	*]	 	 	 	 	 	 	  	Mgmt	  	 	  	$	[	*]	 	0	  	$	[	*]
	 All documentation complete
	  	 	  	 	 	 	 	 	 	 	 	 	  	DEng	  	 	  	$	[	*]	 	0	  	$	[	*]
	 Design Review I (TDR I)
	  	 	  	 	 	 	 	 	 	 	 	 	  	Mach	  	MW	  	$	[	*]	 	1.5	  	$	[	*]
	 	  	 	  	 	 	 	 	 	 	 	 	 	  	CAD	  	 	  	$	[	*]	 	0	  	$	[	*]
	 	  	
	  	
	
	
	 	
	
	
	 	 	  	 	  	 	  	 	 	 	 	
	  	
	
	

	 	  	TOTAL	  	$	[	*]	 	$	[	*]	 	 	  	 	  	 	  	 	 	 	 	TOTAL	  	$	[	*]
	 	  	
	  	
	
	
	 	
	
	
	 	 	  	 	  	 	  	 	 	 	 	
	  	
	
	

	 	  	Phase Total	 	 	$	[	*]	 	 	  	 	  	 	  	 	 	 	 	 	  	 	 	 
									
	 Design Phase
	  	 	 	 	 	 	 	 	 	 	  	 	  	 	  	 	 	 	 	 	  	 	 	 
	 (Estimated Task Duration: 5/7/01 through 7/10/01)(8 wks)
	  	 	  	 	  	 	 	 	 	 	  	 	 	 
								
	 	 	 	 	 	 	 	  	 	  	 	  	/Hr

	 	 	 	  	 	 
	 Deliverable

	  	LT/Date

	  	Mat’l Cost

	 	 	Labor

	 	 	 Comments

	  	Who

	  	Init*

	  	Rate

	 	 	Pwks

	  	Total

	 
	 Complete Overall Design
	  	8 weeks	  	 	 	 	 	 	 	 	 	 	  	Mgmt	  	JS	  	$	[	*]	 	4	  	$	[	*]
	 Build/Test Prototypes (5 Instr.)
	  	6 weeks	  	$	[	*]	 	 	 	 	 	 	  	DEng	  	TD	  	$	[	*]	 	8	  	$	[	*]
	 Build Chronic Prototypes (5)
	  	4 weeks	  	$	[	*]	 	 	 	 	 	 	  	Mach	  	MW, AH	  	$	[	*]	 	16	  	$	[	*]
	 Maintain Chronic Prototypes
	  	As Req’d	  	 	 	 	 	 	 	 	 	 	  	CAD	  	RN	  	$	[	*]	 	8	  	$	[	*]
	 	  	 	  	 	 	 	 	 	 	 	 	 	  	 	  	 	  	 	 	 	 	
	  	
	
	

	 Build Biocompatibility Models
	  	4 weeks	  	$	[	*]	 	 	 	 	 	 	  	 	  	 	  	 	 	 	 	TOTAL	  	$	[	*]
	 	  	 	  	 	 	 	 	 	 	 	 	 	  	 	  	 	  	 	 	 	 	
	  	
	
	

	 Drawings/BoM Complete
	  	4 weeks	  	 	 	 	 	 	 	 	 	 	  	 	  	 	  	 	 	 	 	 	  	 	 	 
	 Packaging Design
	  	2 weeks	  	 	 	 	 	 	 	 	 	Pouch, Boxes, Labels	  	 	  	 	  	 	 	 	 	 	  	 	 	 
	 Design FMEA
	  	2 weeks	  	 	 	 	 	 	 	 	 	 	  	 	  	 	  	 	 	 	 	 	  	 	 	 
	 Design Review II (TDR II)
	  	 	  	 	 	 	 	 	 	 	 	 	  	 	  	 	  	 	 	 	 	 	  	 	 	 
	 	  	
	  	
	
	
	 	
	
	
	 	 	  	 	  	 	  	 	 	 	 	 	  	 	 	 
	 	  	TOTAL	  	$	[	*]	 	$	[	*]	 	 	  	 	  	 	  	 	 	 	 	 	  	 	 	 
	 	  	
	  	
	
	
	 	
	
	
	 	 	  	 	  	 	  	 	 	 	 	 	  	 	 	 
	 	  	Phase Total	 	 	$	[	*]	 	 	  	 	  	 	  	 	 	 	 	 	  	 	 	 
										
	 Tooling Phase
	  	 	  	 	 	 	 	 	 	 	 	 	  	 	  	 	  	 	 	 	 	 	  	 	 	 
	 (Estimated Task Duration: 7/10/01 through 8/30/01)(7wks)
	  	 	  	 	 	 	 	 	  	 	 	 
								
	 	 	 	 	 	 	 	  	 	  	 	  	/Hr

	 	 	 	  	 	 
	 Deliverable

	  	LT/Date

	  	Mat’l Cost

	 	 	Labor

	 	 	 Comments

	  	Who

	  	Init*

	  	Rate

	 	 	Pwks

	  	Total

	 
	 Tooling Equipment Review
	  	 	  	 	 	 	 	 	 	 	 	 	  	Mgmt	  	JS	  	$	[	*]	 	4	  	$	[	*]
	 Make Part Tooling
	  	7 weeks	  	$	[	*]	 	 	 	 	 	4 model Makers/machinists Full-time for both tasks	  	MfgE	  	JP	  	$	[	*]	 	4	  	$	[	*]
	 Make Process Equipment/Gaging
	  	7 weeks	  	$	[	*]	 	 	 	 	 	  	MEng	  	TR	  	$	[	*]	 	7	  	$	[	*]
	 Order Packaging Materials
	  	2 weeks	  	$	[	*]	 	 	 	 	 	 	  	Mach	  	ALL	  	$	[	*]	 	28	  	$	[	*]
	 Tooling Qualification
	  	2 weeks	  	 	 	 	 	 	 	 	 	1st Article,	  	CAD	  	RN	  	$	[	*]	 	7	  	$	[	*]
	 Pre-Pilot Build (10 Instruments)
	  	3 weeks	  	$	[	*]	 	 	 	 	 	$[*] each + [*]% scrap	  	Hourly	  	CT	  	$	[	*]	 	6	  	$	[	*]
	 	  	 	  	 	 	 	 	 	 	 	 	 	  	 	  	 	  	 	 	 	 	
	  	
	
	

	 Design Review III (TDR III)
	  	 	  	 	 	 	 	 	 	 	 	 	  	 	  	 	  	 	 	 	 	TOTAL	  	$	[	*]
	 	  	 	  	 	 	 	 	 	 	 	 	 	  	 	  	 	  	 	 	 	 	
	  	
	
	

	 Make Pilot Components
	  	3 weeks	  	 	 	 	 	 	 	 	 	Machinists + Hourly	  	 	  	 	  	 	 	 	 	 	  	 	 	 
	 	  	
	  	
	
	
	 	
	
	
	 	 	  	 	  	 	  	 	 	 	 	 	  	 	 	 
	 	  	TOTAL	  	$	[	*]	 	$	[	*]	 	 	  	 	  	 	  	 	 	 	 	 	  	 	 	 
	 	  	
	  	
	
	
	 	
	
	
	 	 	  	 	  	 	  	 	 	 	 	 	  	 	 	 
	 	  	Phase Total	 	 	$	[	*]	 	 	  	 	  	 	  	 	 	 	 	 	  	 	 	 
					
	 Pilot Phase (PMBS Build)
	  	 	  	 	 	 	 	 	  	 	 	 
	 (Estimated Task Duration: 8/15/01 through 10/01/01)(6wks)
	  	 	  	 	 	 	 	 	  	 	 	 
								
	 	 	 	 	 	 	 	  	 	  	 	  	/Hr

	 	 	 	  	 	 
	 Deliverable

	  	LT/Date

	  	Mat’l Cost

	 	 	Labor

	 	 	 Comments

	  	Who

	  	Init*

	  	Rate

	 	 	Pwks

	  	Total

	 
	 Make Pilot Components
	  	3 weeks	  	 	 	 	 	 	 	 	 	3 Model Maker/ Machinists Full-time for both tasks + Hourly	  	Mgmt	  	JS	  	$	[	*]	 	2	  	$	[	*]
	 Pilot Build (136 Instruments)
	  	6 weeks	  	$	[	*]	 	 	 	 	 	  	MfgE	  	JP	  	$	[	*]	 	6	  	$	[	*]
	 Sterilization Validation
	  	4 weeks	  	 	 	 	 	 	 	 	 	 	  	MEng	  	TR	  	$	[	*]	 	3	  	$	[	*]
	 Packaging Qualification (seal)
	  	2 weeks	  	 	 	 	 	 	 	 	 	 	  	Mach	  	RH,RH	  	$	[	*]	 	18	  	$	[	*]
	 Accelerated Aging (B Instr.)
	  	4 weeks	  	 	 	 	 	 	 	 	 	Pull from Pilot	  	CAD	  	RN	  	$	[	*]	 	4	  	$	[	*]
	 Design Verification Testing
	  	2 weeks	  	 	 	 	 	 	 	 	 	 	  	Hourly	  	CT	  	$	[	*]	 	12	  	$	[	*]
	 	  	 	  	 	 	 	 	 	 	 	 	 	  	 	  	 	  	 	 	 	 	
	  	
	
	

	 Design Review IV (TDR IV)
	  	 	  	 	 	 	 	 	 	 	 	 	  	 	  	 	  	 	 	 	 	TOTAL	  	$	[	*]
	 	  	
	  	
	
	
	 	
	
	
	 	 	  	 	  	 	  	 	 	 	 	
	  	
	
	

	 	  	TOTAL	  	$	[	*]	 	$	[	*]	 	 	  	 	  	 	  	 	 	 	 	 	  	 	 	 
	 	  	
	  	
	
	
	 	
	
	
	 	 	  	 	  	 	  	 	 	 	 	 	  	 	 	 
	 	  	Phase Total	 	 	$	[	*]	 	 	  	 	  	 	  	 	 	 	 	 	  	 	 	 
		
	 Design Phase Commercial-Design Freeze
	  	 	 	 
	 (Estimated Task Duration: 7/19/01 through 10/11/01)(11wks)(Overlaps with PMBS Pilot)
	  	 	 	 
								
	 	 	 	 	 	 	 	  	 	  	 	  	/Hr

	 	 	 	  	 	 
	 	  	 	  	Who

	  	Init*

	  	Rate

	 	 	Pwks

	  	Total

	 
	 Deliverable

	  	LT/Date

	  	Mat’l Cost

	 	 	Labor

	 	 	 Comments

	  	  	  	 	  
	 Functional Prototypes
	  	6 weeks	  	$	[	*]	 	 	 	 	 	 	  	Mgmt	  	GD	  	$	[	*]	 	0.5	  	$	[	*]
	 Final Appearance Model
	  	2 weeks	  	$	[	*]	 	 	 	 	 	 	  	Eng	  	TR	  	$	[	*]	 	3	  	$	[	*]
	 Drawing and Databases
	  	4 weeks	  	 	 	 	 	 	 	 	 	 	  	Mach	  	MW.AH	  	$	[	*]	 	12	  	$	[	*]
	 Design Review (Design Freeze)
	  	 	  	 	 	 	 	 	 	 	 	 	  	CAD	  	RN	  	$	[	*]	 	4	  	$	[	*]
	 	  	 	  	
	
	
	 	
	
	
	 	 	  	 	  	 	  	 	 	 	 	
	  	
	
	

	 	  	TOTAL	  	$	[	*]	 	$	[	*]	 	 	  	 	  	 	  	 	 	 	 	TOTAL	  	$	[	*]
	 	  	 	  	
	
	
	 	
	
	
	 	 	  	 	  	 	  	 	 	 	 	
	  	
	
	

	 	  	Phase Total	 	 	$	[	*]	 	 	  	 	  	 	  	 	 	 	 	 	  	 	 	 
		
	 Production Tooling Phase/Engineering Pilot Phase **
	  	 	 	 
	 (Estimated Task Duration: 10/11/01 through 2/28/02)(17 wks)
	  

								
	 	 	 	 	 	 	 	  	 	  	 	  	/Hr

	 	 	 	  	 	 
	 Deliverable

	  	LT/Date

	  	Mat’l Cost

	 	 	Labor

	 	 	 Comments

	  	Who

	  	Init*

	  	Rate

	 	 	Pwks

	  	Total

	 
	 Pilot Build (100)
	  	6 weeks	  	$	[	*]	 	 	 	 	 	100 more PMBS Configuration Instr.	  	Mgmt	  	GD	  	$	[	*]	 	4.25	  	$	[	*]
	 Engineering Pilot (100)
	  	6 weeks	  	$	[	*]	 	 	 	 	 	100 Engineering Pilot Instr.	  	Eng	  	TR	  	$	[	*]	 	8	  	$	[	*]
	 	  	 	  	 	 	 	 	 	 	 	 	 	  	Mach	  	MW	  	$	[	*]	 	17	  	$	[	*]
	 	  	TOTAL	  	$	[	*]	 	$	[	*]	 	 	  	CAD	  	RN	  	$	[	*]	 	12	  	$	[	*]
	 	  	Phase Total	 	 	$	[	*]	 	 	  	MfgE	  	 	  	$	[	*]	 	 	  	$	[	*]
	 	  	 	 	 	 	 	 	 	 	  	Hourly	  	CT	  	$	[	*]	 	17	  	$	[	*]
	 	  	 	  	 	 	 	 	 	 	 	 	 	  	 	  	 	  	 	 	 	 	
	  	
	
	

	 Travel (Supplier Visits........)
	  	 	  	 	 	 	 	$	[	*]	 	10 Trips @ $[*]/trip	  	 	  	 	  	 	 	 	 	TOTAL	  	$	[	*]
	 	  	 	  	 	 	 	 	 	 	 	 	 	  	 	  	 	  	 	 	 	 	
	  	
	
	

	 	  	 	 	 	 	 	 	 	 	  	 	  	 	  	 	 	 
	 TOTAL Project Expense
	  	$	[	*]	 	$	[	*]	 	 	  	 	  	 	  	 	 	 
	 	  	 	 	 	$	[	*]	 	 	  	 	  	 	  	 	 	 

  

	**	$* budgeted for capital equipment (Enable or Other Suppliers) - To Be Determined 

  

			
	 *Inits:
	  	[*]=[*] (Mgmt)
	 	  	[*]=[*] (Meng)
	 	  	[*]=[*] (Mach)
	 	  	[*]=[*] (Mach)
	 	  	[*]=[*] (Mach)
	 	  	[*]=[*] (Mach)
	 	  	[*]=[*] (CAD)
	 	  	[*]=[*] (CAD)
	 	  	[*]=[*] (MfgE)
	 	  	CT=Contract
	 	  	ALL=All Machinists

  

  

	[*]	Certain information on this page has been omitted and filed separately with the Securities and Exchange Commission. Confidential treatment has been requested with respect to the
omitted portions. 

 Technology Transfer Agreement 
 Page 16 
  

 The Service Agreement 
  
 Budget 
  

 3/25/01 
  
 AtriCure 
  
 Enable Budget for PMBS Hand-Piece Development 
  
 Ongoing Design Development Support 
  

															
	 	 	 	  	Monthly Charge

	 	 	May
- Feb
02

	 
	 Resource

	 	 Task

	  	To
9/30/01

	 	 	10/1-2/2

	 	 	Total

	 
	 CAD Designera
	 	 Detail Design of Hand-piece and Cable
	  	$	[	*]	 	$	[	*]	 	 	 	 
	 Engineer w/ CADb
	 	 Design Support of Generator & Misc
	  	$	[	*]	 	$	[	*]	 	 	 	 
	 Project Managementc
	 	 Coordination of all Hand-piece Development
	  	$	[	*]	 	$	[	*]	 	 	 	 
	 	 	 	  	
	
	
	 	
	
	
	 	 	 	 
	 	 	 	  	$	[	*]	 	$	[	*]	 	$	[	*]
	 Support for Systems (Pro-E, Visual,...) and Ken Miller (Facility & Shop mat’ls)
	  	$	[	*]	 	$	[	*]	 	 	 	 
	 License for Enable technology (thru August 2001 - $[*] total)
	  	$	[	*]	 	 	 	 	 	 	 	 
	 	 	 	  	
	
	
	 	
	
	
	 	 	 	 
	 	 	 	  	$	[	*]	 	$	[	*]	 	$	[	*]
	 Sub-total
	 	 	  	$	[	*]	 	$	[	*]	 	 	 	 
	 	 	 	  	
	
	
	 	
	
	
	 	 	 	 

  

											
	 Phase Payment

	 	 Phase Deliverables

	  	Cost per Device

	 	 	Total

	 
	 Technical Design Review 1 (Feasibility Phase)
	  	 	 	 	 	$	[	*]
	 	 	 Build 2 form models and modifications (ie. Degree of angle)
	  	 	 	 	 	 	 	 
	 	 	 All documentation for design review
	  	 	 	 	 	 	 	 
	 	 	 	  	 	 	 	 	
	
	

	 Technical Design Review 2 (Design Phase)
	  	 	 	 	 	$	[	*]
	 	 	 Build 5 chronic models
	  	 	 	 	 	 	 	 
	 	 	 Re-build and maintain models through chronic studies
	  	 	 	 	 	 	 	 
	 	 	 Risk analysis (FMEAs)
	  	 	 	 	 	 	 	 
	 	 	 Bio-Compatability (12 Distal End Assemblies by 8/10/01)d
	  	$	[	*]	 	$	[	*]
	 	 	 All documentation for design review
	  	 	 	 	 	 	 	 
	 	 	 	  	 	 	 	 	
	
	

	 Technical Design Review 3 (Tooling Phase)
	  	 	 	 	 	$	[	*]
	 	 	 Equipment, tooling and fixtures designed and built
	  	 	 	 	 	 	 	 
	 	 	 First articles completed on all parts
	  	 	 	 	 	 	 	 
	 	 	 Documentation of procedures and controls complete
	  	 	 	 	 	 	 	 
	 	 	 Packaging design and test (pouch)
	  	 	 	 	 	 	 	 
	 	 	 Packaging seal qualification (pouch)
	  	 	 	 	 	 	 	 
	 	 	 Pre-Pilot Build (10 devices by 8/22/01)
	  	$	[	*]	 	$	[	*]
	 	 	 All documentation for design review
	  	 	 	 	 	 	 	 
	 	 	 	  	 	 	 	 	
	
	

	 Technical Design Review 4 (Pilot Phase)
	  	 	 	 	 	$	[	*]
	 	 	 Pilot Build (136 Packaged Devices by 9/11/01)e,f
	  	$	[	*]	 	$	[	*]
	 	 	 Post Pilot Samples (20 Non packaged devices by 10/15/01)g
	  	$	[	*]	 	$	[	*]
	 	 	 All documentation for design review
	  	 	 	 	 	 	 	 
	 	 	 	  	 	 	 	 	
	
	

	 Production Instrument (Design Freeze Phase)
	  	 	 	 	 	$	[	*]
	 	 	 Functional Prototypei
	  	 	 	 	 	 	 	 
	 	 	 Final Appearance Model
	  	 	 	 	 	 	 	 
	 	 	 All drawings and database
	  	 	 	 	 	 	 	 
	 	 	 	  	 	 	 	 	
	
	

	 Engineering Pilot Phase
	  	 	 	 	 	$	[	*]
	 	 	 Pilot Build (100 devices by 3/1/02)j
	  	$	[	*]	 	$	[	*]
	 	 	 Pilot Build #2 (100 Packaged Devices by 1/15/02)h
	  	$	[	*]	 	$	[	*]
	 	 	 	  	 	 	 	 	
	
	

			
	 	 	 	  	Project Payments thru Feb ’02

	 
	 	 	 Travel
	  	 	 	 	 	 	[	*]
	 	 	 Total Monthly Payments
	  	 	 	 	 	$	[	*]
	 	 	 Total Milestone Payments
	  	 	 	 	 	$	[	*]
	 	 	 	  	 	 	 	 	
	
	

	 	 	 Project Total
	  	 	 	 	 	$	[	*]
	 	 	 	  	 	 	 	 	
	
	

  
 Enable Partnership Milestones 
  

	[*]	Certain information on this page has been omitted and filed separately with the Securities and Exchange Commission. Confidential treatment has been requested with respect to the
omitted portions. 

 3/25/01 
  
 AtriCure 
  
 Enable Budget for PMBS Hand-Piece Development 
  
 Footnotes/Assumptions 
  

									
	a	  	25 hrs/wk @ [*]	  	 	  	 	  	 
	b	  	40 hrs/wk to Oct 1 @ $[*] // 20-25 hrs/wk @ $[*]	  	 	  	 
	c	  	20-25 hrs/wk to Oct 1 @ $[*] //10-15 hrs/wk @ $[*]	  	 	  	 
	d	  	2 people, 2wks + sterilization	  	 	  	 	  	 
	e	  	 	  	 Materials
	  	[*]	  	[*]%
	 	  	 	  	 Labor
	  	[*]	  	3 people - 1 mo @ $[*]m ea
	 	  	 	  	 	  	
	  	 
	 	  	 	  	 Direct costs
	  	[*]	  	 
	 	  	 	  	 Scrap factor
	  	[*]	  	[*]%
	 	  	 	  	 	  	
	  	 
	 	  	 	  	 	  	[*]	  	 
	 	  	 	  	 Overhead
	  	[*]	  	 
	 	  	 	  	 Sterilization
	  	[*]	  	$[*]/lot ($[*] plus ins & shipping)
	 	  	 	  	 	  	
	  	 
	 	  	 	  	 	  	[*]	  	 
	 	  	 	  	 Profit
	  	[*]	  	[*]% markup
	 	  	 	  	 	  	
	  	 
	 	  	 	  	 	  	[*]	  	 
	 	  	 	  	 Rounded - use
	  	[*]	  	 
	f	  	Yield 30 saleable kits	  	 	  	 	  	 
	g	  	Sterilization costs removed	  	 	  	 	  	 
	h	  	Yield 50 saleable kits	  	 	  	 	  	 
	i	  	2 model makers / 2 months	  	 	  	 	  	 
	j	  	Assumed Built At Enable ([*]% COGS)	  	 	  	 

  
 Enable Partnership Milestones 
  

  

	[*]	Certain information on this page has been omitted and filed separately with the Securities and Exchange Commission. Confidential treatment has been requested with respect to the
omitted portions.

Source: [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00087-of-00352.parquet"}, [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00087-of-00352.parquet"}]]